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Abstract 
 
 Cellular or viral delivery of anti-cancer gene therapeutics typically has been 
investigated as single agents. More recently combinatorial agents have been investigated 
for which some combinations have shown synergism. The present study was designed to 
evaluate three different potential anticancer factors, decorin, interferon beta (IFNb), 
and tumor necrosis factor (TNF) related apoptotic inducing ligand (TRAIL).  The overall 
hypothesis was that combinatorial treatment of two of anti-cancer factors would be more 
efficacious and exhibit less toxicity than single treatments in breast cancer cell lines.     
In order to be able to test this hypothesis, the construction of these anticancer 
genes was required as well as engineering and expression of transgenes in a cellular 
production system.  Therefore, my thesis project required the isolation of anti-cancer 
genes from either human genomic or cDNA libraries, verification of sequence fidelity, 
construction of transgene expression cassettes, and transient transfection of the 
transgenes in Chinese hamster ovarian (CHO) cells.  Secreted cellular protein production 
was verified in culture media and the anti-cancer effects of conditioned media containing 
single proteins on growth of human and mouse breast cancer cell lines was measured and 
compared to commercially available agents.    
Mesenchymal stem cells (MSCs) have been shown to home to tumors and are 
under investigation as vehicles for delivering anticancer gene therapeutics. MSC-based 
anti-cancer gene therapeutics are typically investigated as single agents.  The present 
study was designed to assess the anti-cancer properties of the selected gene products as a 
prelude to their production from MSCs. This study specifically evaluated decorin, 
interferon beta (IFNb), and tumor necrosis factor (TNF) related apoptotic inducing ligand 
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(TRAIL) as growth inhibitors in vitro as previous studies have demonstrated their 
efficacy as growth inhibitors in multiple cancer cell lines including breast cancer in in 
vitro and in vivo studies. My experimental results indicated that commercially available 
human and mouse TRAIL inhibited MDA-MB-231, MCF-7, and WM793 human cancer 
cell lines. TRAIL produced by CHO cells were able to decrease WM793 cancer cell 
growth, but not illicit a response in MDA-MB-231 or MCF-7 breast cancer cell lines. 
Further studies are needed to discover the relationship between the combination of these 
gene products. 
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Chapter 1: Introduction 
 
1.1 - Cancer Background 
Cancer is a group of diseases that encompass a diverse set of phenotypic and 
genotypic mutations to specific cell types.  This group of diseases is characterized by an 
uncontrolled growth and spread of abnormal cells (American Cancer Society 2013). 
Cancer can be caused by extrinsic and intrinsic factors such as environmental or inherited 
conditions. These factors may interact together to initiate and proliferate cancer events. 
Generally speaking, cancer can be treated by various combinations of surgery, radiation, 
chemotherapy, hormone therapy, biological therapy, and targeted therapy. In 2013, it is 
estimated that 1,660,290 new cancers will be diagnosed and 580,350 people will die from 
cancer (American Cancer Society 2013). In 2008, the cost of cancer was 201.5 billion 
USD (77.4 billion USD in direct healthcare costs) (American Cancer Society 2013).  
Specific to breast cancer, 230,480 new invasive and 57,650 in situ cases occurred 
in 2011 (American Cancer Society 2012). The median age for developing breast cancer is 
61 years old and it is estimated that one in eight women will develop breast cancer by the 
age of 70. Being a female, being above 65 years of age, possessing BRCA1 and/or 
BRCA2 mutations, having more than two 1st degree relatives diagnosed with breast 
cancer at an early age, having a personal history of breast cancer, having high breast 
tissue density, or having a confirmed biopsy showing atypical hyperplasia increase the 
relative risk of developing breast cancer by more than 4 fold increase. Having one first 
degree relative with breast cancer, a prior history of high dose radiation to the chest, or a 
high bone density post menopause increases the relative risk of developing breast cancer 
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by 2.1-4 fold increase. Late age at first full term pregnancy, early menarche, late 
menopause, no full term pregnancies, not having breastfed, recent oral contraceptive use, 
recent/long term use of estrogen and progestin, or postmenopausal obesity increases the 
relative risk of developing breast cancer by 1.1- 2.0 fold increase. Personal history of 
endometrial or ovarian cancer, elevated alcohol consumption, increased height, higher 
socioeconomic status, or Ashkenazi Jewish lineage are also factors that increase the risk 
of developing breast cancer (American Cancer Society 2012). Besides grades and stage 
of breast cancers, breast cancer has been further classified into different types depending 
on the expression of specific mitogenic proteins including estrogen receptor (ER), 
progesterone receptor (PR), and HER2 (ErbB2 in mouse), as well as morphology. 
Cancers expressing ER and/or PR yields a more favorable prognosis than ER-/PR- breast 
cancers due largely to the likelihood of their response to selective estrogen receptor 
modulators that block estrogen effects. A subset of breast cancers that express HER2 
respond to the specific anti-cancer agents such as trastuzumab. Other classifications are 
triple negative, which is ER-/PR-/HER2- cancers that are associated with poor clinical 
outcomes. Efficacy of established therapeutics is dependent on the grade, stage, and 
ER/PR/HER2 status of breast cancers, therefore the design and testing of novel 
therapeutics must be evaluated in models that represent these varied types. 
 
1.2 - TNF-Related Apoptosis-Inducing Ligand  
TNF-related apoptosis-inducing ligand (TRAIL), mediated through a FAS 
independent pathway, induces apoptosis in many transformed cell lines (Wiley et al. 
1995 and Pitti et al. 1996). TRAIL is characterized as a type II membrane protein with 
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homology to the TNF ligand family that interacts with specific receptors for TRAIL 
(Wiley et al. 1995 and Pitti et al. 1996). TRAIL receptor and TRAIL form a hexameric 
complex resulting from a stable homotrimer TRAIL ligand with 3 receptor units 
(Hymowitz et al. 1999). TRAIL ligand, at amino acid residues 119 through 281 and 
TRAIL receptor at amino acid residues 21 though 130 were found to be the point of 
interaction between the two proteins (Hymowitz et al. 1999). The first receptor identified 
for TRAIL was the DR4 or TRAIL-R1. The resultant apoptosis from the interaction of 
the TRAIL-R1 receptor and ligand pair were abrogated with the use of caspase inhibitors, 
indicating that caspases are involved in mediating the TRAIL/TRAIL receptor mediated 
apoptosis (Pan et al. 1997a). The second receptor mediating a TRAIL induced apoptotic 
response was found after the discovery of the first receptor and named DR5 (Pan et al. 
1997b) or TRAIL-R2 (Sheridan et al. 1997). TRAIL-R2 showed a 66% extracellular 
region amino acid identity with TRAIL-R1 (Pan et al. 1997b). An over-expression of 
TRAIL-R2 induced cell death by apoptosis through the activation of FADD and caspases 
(Walczak et al. 1997). A decoy receptor TRAIL-R3, originally identified as DcR1 
(Sheridan et al. 1997) or TRID (Pan et al. 1997b), showed a 69% and 52% amino acid 
homology with the extracellular regions of TRAIL-R1 and TRAIL-R2 respectively. An 
additional decoy receptor, TRAIL-R4 was identified by Degli-Esposti et al. (1997). The 
extra cellular domain identity of TRAIL-R4 was 58%, 57%, and 70% to TRAIL-R1, 
TRAIL-R2, and TRAIL-R3 respectively (Degli-Esposti et al. 1997). Various experiments 
attempting to identify the relationship between the receptors and their susceptibility to 
TRAIL have been conducted using various means. 
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TRAIL-R3 and TRAIL-R4 were discovered to block the apoptotic effect of 
TRAIL. Cells that originally displayed sensitivity to TRAIL mediated apoptosis 
conferred resistance when transfected with TRAIL-R3 (Sheridan et al. 1997) or TRAIL-
R4 (Degli-Esposti et al. 1997).  It was reported that TRAIL-R3 was found in normal 
tissues but not present in many tumors (Sheridan et al. 1997). TRAIL-R4 was found to 
have high tissue expression (Degli-Esposti et al. 1997). For tumors expressing TRAIL-
R3, the transcript level of the R3 receptor did not correlate to the sensitivity of TRAIL 
administration (Keane et al. 1999).  TRAIL-R4 differs from TRAIL-R3 in that it can 
activate the NFκb pathway but cannot induce apoptosis (Degli-Esposti et al. 1997). The 
fifth TRAIL receptor, Osteoprotegerin, was found to be a soluble antagonist receptor for 
TRAIL, potentially blocking the effects of TRAIL (Emery et al. 1998). Little is known 
about the relationship of the fifth receptor and TRAIL and it might be of practical and 
clinical significance to further clarify its role in TRAIL signaling. Although TRAIL-R1 
and TRAIL-R2 have been identified as critical components in the mediation of the 
apoptotic signal from TRAIL, studies investigating knockouts and knockdowns of either 
TRAIL-R1 or TRAIL-R2 indicate that TRAIL-R2 is more important in mediating the 
apoptotic signal from the administration of TRAIL (Goda et al. 2008 and Rahman et al. 
2009). A TRAIL-R2 knockdown had the same effect as a TRAIL-R1 and TRAIL-R2 
knockdown, whereas a TRAIL-R1 knockdown had no effect on reducing apoptosis after 
the administration of TRAIL to TRAIL sensitive cells (Goda et al. 2008). Rahman et al. 
(2009) used MDA-MB-231 breast cancer cells (triple negative breast cancer subtype) to 
create knockouts for TRAIL-R1 and TRAIL-R2. It was found that the TRAIL-R1 
knockout in these cells had no effect on inhibiting apoptosis after a TRAIL 
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administration in vitro. However this study found that TRAIL-R2 knockout in MDA-
MB-231s inhibited apoptosis mediated by TRAIL.  
Several initial studies of TRAIL receptors measured transcript alone instead of 
cellular surface expression. It was later found that mRNA of TRAIL-R1 and TRAIL-R2 
does not correlate to TRAIL sensitivity of cell lines (Zhang et al. 2008). It was shown 
that TRAIL-R1 linked to a green fluorescent protein reporter (GFP) was located in the 
cytoplasm for TRAIL resistant cells and receptors located on the cellular surface for 
TRAIL sensitive cells (Zhang et al. 2008). Endocytosis of TRAIL receptors may 
contribute to TRAIL resistance as shown by sensitization of resistant cell lines to TRAIL 
after the administration of endocytosis inhibitors (Zhang et al. 2008). The administration 
of endocytosis inhibitors resulted in MDA-MB-231 cells that were sensitive to TRAIL, a 
greater sensitivity to TRAIL, and greater apoptosis in vitro (Zhang et al. 2009). Ganten et 
al. (2009) analyzed 311 tumors from breast cancer patients and found that the presence of 
TRAIL-R2 and TRAIL-R4 correlated with bad clinical prognostic markers for overall 
survival while the presence of TRAIL-R1 correlated with good prognostic markers. 
Immunohistochemistry was used in the 311 breast cancer samples and TRAIL-R1 was 
found to be located in both the cytoplasm and membrane regions while TRAIL-R2 was 
seen mostly in the cytoplasm (Ganten et al. 2009).  TRAIL-R3 was not found to be a 
predictor of clinical outcome (Ganten et al. 2009). TRAIL-R3 may however play in 
important role with the molecular involvement of TRAIL signaling. This data highlights 
an area of clinical importance where the use of TRAIL may be beneficial.  
MDA-MB-231 cells, which are highly sensitive to TRAIL, can become resistant 
to TRAIL after a prolonged exposure to sub-toxic doses of TRAIL resulting in 
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irreversible resistance to TRAIL (Yoshida et al. 2009). During the sub-toxic 
administration of TRAIL, transcripts for TRAIL-R1, -R2, -R3, and -R4 all remained the 
same as compared to untreated cells however the surface expression of TRAIL-R1 and 
TRAIL-R2 decreased significantly (Yoshida et al. 2009). 
While TNF and FasL have shown to be excellent at causing apoptosis in cancer 
cells, they have however shown to elicit severe toxicity to normal hepatocytes and other 
cells (Ashkenazi et al. 1999). TRAIL, did not show initial toxicity to normal cells, but 
had an apoptotic effect on 32 of 39 cell lines in colon, lung, breast, kidney, brain, and 
skin cancer (Ashkenazi et al. 1999). TRAIL did not cause toxicity in primates and the 
addition of TRAIL caused apoptosis in solid tumors, suppressed tumor progression, and 
improved survival (Ashkenazi et al. 1999). These results indicate that TRAIL has the 
potential to be an effective method for the treatment of various cancers in diverse tissues. 
Further studies involving TRAIL highlighted potential issues with TRAIL causing 
hepatocyte cell death (Ozoren et al. 2000). However, Walczak et al. (1999) had found 
that TRAIL had not shown any signs of toxicity to liver, brain, and other tissue. 
Lawrence et al. (2001) were able to show that the hepatic apoptosis was caused by His-
tagged TRAIL (polyhistidine epitope tagged TRAIL). His-tagged TRAIL was found to be 
unstable in solution and had formed insoluble aggregates at 37°C. Not only was His-
tagged TRAIL less potent than inducing apoptosis in tumor cell lines than normal 
TRAIL, but apoptosis seen in His-tagged TRAIL with human hepatocytes was not seen 
from normal TRAIL at a concentration 1000X that of His-tagged TRAIL (Lawrence et al. 
2001). TRAIL was administered to nonhuman primates and had all tissues analyzed for 
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apoptotic or pathologic effect (Lawrence et al. 2001). These results indicate that TRAIL 
is safe on human hepatocytes and nonhuman primate models as well.    
Besides active TRAIL-R1 and TRAIL-R2 transcriptional activity and functioning 
proteins expressed on the cellular surface, signaling proteins that mediate the propagation 
of both extrinsic and intrinsic apoptotic pathways are needed. FADD (Fas-associated 
death domain) and caspase 8 are recruited to the receptor and induce apoptosis through 
caspase activation (Suliman et al. 2001). The pathway was verified by testing knockouts 
of either FADD or caspase 8. Cells deficient in FADD or caspase 8 blocked TRAIL 
mediated apoptosis (Suliman et al. 2001). Caspase 8 was found to activate caspase 3 
indicating the major contributors to TRAIL mediated apoptosis (Suliman et al. 2001).  
FLIP (Flice Inhibitory Protein) inhibits FADD, therefore inhibits apoptotic 
signaling (Ricci et al. 2004). C-myc binds to the FLIP gene promoter resulting in a 
repressed FLIP transcription and protein expression (Ricci et al. 2004). C-myc levels in 
tumor lines formed a linear relationship between responsiveness to TRAIL mediated 
apoptosis. The more c-myc that is present results in lower amounts of FLIP. A lower 
amount of FLIP results in a lower inhibition to FADD. Through an engineering knock 
down of sensitive cell lines and a molecular knock in to resistant cell lines, TRAIL 
mediated apoptosis could be controlled by amounts of c-myc present (Ricci et al. 2004). 
The higher c-myc levels resulted in the greater sensitivity to TRAIL (Ricci et al. 2004). 
 The initial experiments related to TRAIL mediated apoptosis indicate the 
importance of and dependence to several cellular characteristics and the protein 
expression of certain genes. Alone, TRAIL represents a strong candidate for the treatment 
of breast cancer. The aforementioned studies indicate TRAIL as a potentially efficacious 
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and safe treatment for breast cancer. Other studies have attempted to use the apoptotic 
properties of TRAIL as a combinatorial or adjuvant therapy along with other established 
anticancer treatments. TRAIL has increased apoptosis of various cancers with the 
addition of trastuzumab (Cuello et al. 2001), tamoxifen (Ricci et al. 2004 and Lagadec et 
al. 2008), ionizing radiation (Shankar et al. 2004), interferons (Chawla-Sarkar et al. 2002 
and Kumar-Sinha et al. 2002), and a wide variety of chemotherapies that influenced 
mediator caspases of TRAIL induced apoptosis (Thai et al. 2006). Several 
chemotherapeutics have shown a synergistic interaction with TRAIL causing apoptosis in 
various cancer lines in vitro and in vivo. Keane et al. (1999) showed this synergistic 
relationship was related only to chemotherapeutics that activated similar caspases that are 
involved in TRAIL mediated apoptosis. Not only has chemotherapy shown to increase 
caspase activity, but it has also been shown to upregulate TRAIL-R1 and TRAIL-R2 after 
24 and 48 hours in vivo (Singh et al. 2003). A chemotherapeutic pretreatment 24 hours 
prior to the administration of systemically delivered TRAIL in a mouse model of breast 
cancer illustrated a significant survival increase of the animals over TRAIL or 
chemotherapy alone without the observation of liver or brain toxicity (Singh et al. 2003). 
This data supports the use of TRAIL used in combination with treatments efficacious for 
certain types of cancers resulting in potential synergistic apoptosis effects of malignant 
cells.  
Tamoxifen has shown to be efficacious in the treatment of ER positive breast 
cancer in humans which occurs in 60 to 70% of primary breast cancer incidences 
(Osborne 1998). A mouse model using MDA-MB-231 or MCF7 human breast cancer 
cells were shown to exhibit synergistic apoptotic effects from the use of TRAIL and 
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tamoxifen (Lagadec et al. 2008). While tamoxifen alone did not influence apoptosis in 
ER negative breast cancer cells, with the combination of hTRAIL, synergistic apoptosis 
was observed. The combination of tamoxifen and TRAIL increased caspase 3 
synergistically (Ricci et al. 2004). These results indicate that tamoxifen, with TRAIL are 
able to induce synergistic apoptosis in breast cancer cells in vivo regardless of ER status.  
TRAIL along with trastuzumab caused down regulation of ErbB2 and enhanced 
apoptosis more than either therapeutic alone in breast cancer cells expressing high levels 
of ErbB2 (Cuello et al. 2001). Ionizing radiation has shown to increase TRAIL-R2, 
caspase 8, and sensitivity to hTRAIL (Shankar et al. 2004). The in vivo study involving 
ionizing radiation and TRAIL resulted in complete tumor regression and 100% survival, 
an outcome not seen from TRAIL or ionizing radiation alone (Shankar et al. 2004). 
Clinically, a method used to deliver TRAIL locally as opposed to systemically 
would be a preferable method of delivery. MSCs have been used to deliver TRAIL to 
gliomas and MDA-MB-231 tumors. Yang et al. (2009) found that full length TRAIL 
expressed in MSCs resulted in soluble TRAIL secreted while naive MSC cells did not 
have any secreted TRAIL. MSCs home to some tumor cells, but not to other cancer cells 
(Loebinger et al. 2009). MSCs expressing TRAIL significantly reduced metastatic tumor 
burden, significantly killed lung, breast, squamous cell, and cervical cancer lines 
(Loebinger et al. 2009). These results make the delivery of TRAIL or other therapeutics 
by MSCs as an optimal method for delivery. 
Murine TRAIL (mTRAIL) appears to function similarly to human TRAIL 
(hTRAIL), likely due to sequence homologies. The open reading frame of human TRAIL 
consists of 846 base pairs while mouse TRAIL consists of 876 base pairs. Human and 
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mouse TRAIL share 65% amino acid identity and have shown similar effects to TRAIL 
sensitive cells, regardless of whether or not the cells were of human or mouse origins 
(Wiley et al. 1995 and Pitti et al. 1996). mTRAIL was found to induce apoptosis, 
promote cell death, and increase the doubling time of 4T1 murine mammary carcinoma 
cells in vitro and in vivo (Ganai et al. 2009). From the observations seen in other cell 
lines, both human and mouse TRAIL should affect TRAIL sensitive cells. MCF7 cells 
have caspase 8 and FADD and were found to be susceptible to TRAIL administration 
(Suliman et al. 2001). MDA-MB-231 (Yoshida et al. 2009) and WM793 melanoma cells 
are highly susceptible to TRAIL administration. These features suggest that testing of 
human or mouse TRAIL in cancer cells of human or mouse origin will reveal cell 
specific sensitivities and mechanisms of action.  
 
1.3 - Decorin 
Decorin is a small secreted chondroitin/dermatan sulfate proteoglycan from the 
family of small leucine rich proteoglycans (SLRP). Decorin has been localized to the 
12q21 region of the human genome and mRNA has been found highest in connective 
tissue such as aorta, lung, skin, kidney, smooth muscle, placenta, skeletal muscle, spleen, 
and adrenal gland (Pulkkinen et al. 1992). Decorin is produced and excreted into the 
media when full length decorin cDNA is transfected into CHO cell line (Yamaguchi and 
Ruoslahti 1988) or the WiDr human colon carcinoma cell line (Santra et al. 1995). The 
produced decorin caused a reduction in CHO density and slowed the growth of CHO 
cells in culture (Yamaguchi and Ruoslahti 1988), indicating that decorin may have an 
impact on cell proliferation. Yamaguchi et al. (1990) were able to show that decorin, 
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isolated from bovine skin as well as recombinant decorin produced by CHO cells, were 
able to inhibit TGF-β1 dependent cell growth through decorin inhibition of TGF-β1 
binding. The decorin experiments conducted by Yamaguchi et al. (1988 and 1990) 
provided initial data indicating decorin’s potential impact on inhibiting cellular growth.  
Carcinoma cell lines not affected by TGFβ growth were found to also be 
suppressed by decorin, indicating that decorin interacts with other mechanisms involving 
suppression and reduced growth rate in vitro other than the TGFβ pathway (Santra et al. 
1995). The observed decline and suppression of growth rate correlated to a shift of cell 
population into G1 phase of the cell cycle as compared to control groups not receiving 
decorin (Santra et al. 1995). After observing the antiproliferative effects of decorin on the 
human colon carcinoma cell line, Santra et al. (1995) hypothesized that decorin deletions 
may increase the incidence of tumor formation. Several neoplastic cell lines from various 
tissues exhibited suppressed growth from decorin expressed as a proteoglycan or protein 
core (Santra et al. 1997). The cell lines that showed suppressed cell growth had an 
increase of cells in the G1 phase and experienced an up regulation of p21 mRNA and 
protein (Santra et al. 1997). Several additional findings indicate that neoplastic cells that 
contain a disrupted p21 gene failed to respond to decorin. Decorin acts from outside of 
the cell in a paracrine manner, and that decorin is absent in transformed cell lines (Santra 
et al. 1997). Decorin was also found to bind to the EGFR in the soluble ectodomain 
region (Iozzo et al. 1999). Full length and core decorin protein activates MAPK, 
increases p21, and prolongs cells in G1 (Iozzo et al. 1999). The direct effect of 
prolonging the cells in the G1 phase indicates that decorin has the ability exert an 
antiprolifertive effect on cancer cells.  
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The majority of the antiproliferative effects of decorin was identified at 96 hours 
and later in in vitro experiments using MDA-MB-231 cells, indicating that decorin may 
require a longer period of incubation with the cancer cells of interest than TRAIL or 
IFNb to mediate a measureable effect (Araki et al. 2009). Decorin expressing MDA-MB-
231 cells exhibited growth suppression, reduced motility, and lowered metastasis to bone 
as compared to untreated MDA-MB-231 cells in vivo (Araki et al. 2009). 
Several breast cancers exhibit higher expression levels of ErbB2/HER2 and HER2 
is thought to play a significant role in negatively influencing outcome and therefore 
breast cancer prognosis. Decorin inhibits ErbB2 phosphorylation and overexpression in 
breast carcinomas cells in vitro (Santra et al. 2000). Decorin has been found to reduce 
ErbB2/HER2 through the ErbB4 receptor interactions that resulted in an inhibition of 
primary growth and metastasis in breast cancer cells during systemic administration of 
decorin (Goldoni et al. 2008).  
Decorin was found to act as a paracrine inhibitor of cell growth; decorin 
suppressed EGFR Kinase activity in co-culture experiments involving decorin expressing 
cells (Csordas et al. 2000). Systemic administration of decorin was also shown to down 
regulate EGFR and thereby tumor growth suppression (Hu et al. 2009). 
Decorin has also been shown to trigger apoptosis (Hu et al. 2009 and Goldoni et 
al. 2009). This apoptotic activity was mediated through capsase 3 and 7 (Goldoni et al. 
2009). Decorin, is also a novel inhibitor of the Met Receptor; decorin, dose dependently 
blocked the MET receptor as measured by physical and functional down regulation of 
MET mediated activities (Goldoni et al. 2009). Decorin antagonizing effects on TGFβ1 
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and receptors for MET, EGF, ErbB2 indicate the strong potential for decorin to be used 
for the treatment of breast cancer. 
 
1.4 - Interferon Beta 
Interferon Beta (IFNb), as a member of the interferon gene family, has been 
shown to interfere with viral replication, affect cell motility, inhibit cell proliferation, and 
modulate the immune system (Lengyel 1982). Initial studies had demonstrated interferon 
to be safe to use in human therapy and illustrated the potential to increase estrogen and 
progesterone receptor content in isolated tumor tissue from advanced breast cancer 
metastases (Pouillart et al. 1982). Fierlbeck et al. (1996) measured CHO cell derived 
IFNb levels that had been administered to melanoma patients and found that the IFNb 
level had returned to baseline by 48 hours after subcutaneous administration. This finding 
illustrates the relatively short half-life of IFNb in vivo and the need for a continual 
delivery method to achieve the antiproliferative effects of IFNb on malignant cells. 
Mesenchymal stem cells (MSCs) have been used as vectors in the delivery of 
genes to malignant cells in vivo. Studeny et al. (2002) exhibited the ability of MSCs 
expressing human recombinant interferon beta (hrIFNb) to home to sites of tumor 
formation. The MSCs expressing hrIFNb inhibited growth of human malignant cells in 
vitro and in vivo (Studeny et al. 2002). MSCs expressing hrIFNb has been shown to 
inhibit growth of MDA-MB-231 tumors formed in lung tissue more than systemically 
administered hrIFNb or naive MSCs had inhibited tumors alone (Studeny et al. 2004). 
IFNb derived from purified MSCs cells engineered with hrIFNb inhibited proliferation of 
MDA-MB-231 cells in vitro (Studeny et al. 2004). 
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  IFNb enhances the cytotoxicity caused by chemotherapeutics in vitro 
(Brickelmaier et al. 2002). Several human breast cancer cell lines along with other cancer 
cell lines displayed a variation in susceptibility with different concentrations of hIFNb 
indicating that not all breast cancers will be equally susceptible to IFNb (Brickelmaier et 
al. 2002). The effects seen in the cancer lines from hrIFNb treatment were increased with 
the use of chemotherapeutics (Brickelmaier et al. 2002). MCF-7 human breast cancer 
cells displayed an EC50 of 900 IU/uL of hrIFNb while the EC50 of hrIFNb was 100 
IU/uL in MDA-MB-468 cells (Brickelmaier et al. 2002). With MCF-7 cells showing 
some resistance to hrIFNb administration, it required 1000IU/ml to induce significant 
apoptosis (Kaynor et al. 2002). It has been shown that mIFNb does not exert the same 
effect as hIFNb on tumors created from human MDA-MB-231 cells (Qin et al. 2001). 
Mice treated with hIFNb showed a higher antiproliferative effect on the MDA-MB-231 
cells along with a higher survival rate, than mice treated with mIFNb (Qin et al. 2001). 
These studies indicate hrIFNb exhibits an antiproliferative effect on MDA-MB-231 and 
other breast cancer cell lines making it a good anticancer agent candidate that may prove 
particularly valuable in combination with other gene products. Furthermore these studies 
suggest species specificity of recombinant IFNb. 
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Chapter 2: Material and Methods 
 
2.1 - Engineering Methods 
The initial stage of the project involved identifying genes of interest, designing 
primers for specific genes, amplifying genes from DNA libraries, ligation of the genes 
into plasmid, amplification of plasmids, sequence verification of genes, ligation of genes 
into mammalian expression vectors, and finally producing gene products to be used in 
further experiments. 
 
2.1.1 - Introduction 
TRAIL, IFNb, and decorin were identified as having potential mediating effects 
on various cancer cells. The primers (Table 1) were designed to have sequence homology 
within the human genome towards the specific genes of interest, a Kozak sequence, a 
BamHI cut site, similar melting temperatures, and start or stop codons in order to express 
the respective open reading frames. The melting temperatures were calculated by  
OligoAnalyzer (Integrated DNA Technologies, Coralville, Iowa, USA). 
 Table 1- Primer sequences for anticancer factors 
5' 3'
hrIFNbFOR GGA TCC ACC ATG ACC AAC AAG TGT CTC CTC C
hrIFNbREV GGA TCC TCA GTT TCG GAG GTA ACC TGT AAG
hrTRAILFOR GGA TCC ACC ATG GCT ATG GCT ATG ATG GAG GTC CAG
hrTRAILREV GGA TCC TTA GCC AAC TAA AAA GGC CCC
hrDECORINFOR GGA TCC ACC ATG AAG GCC ACT ATC ATC CTC C
hrDECORINREV GGA TCC TTA CTT ATA GTT TCC GAG TTG AAT GGC A
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2.1.2 - PCR protocol for hrDecorin 
Human recombinant decorin (hrDecorin) was amplified using human ovarian or 
brain cDNA library obtained from Dr. Edward Perkins. The PCR tube contained 1 uL Pfx 
50 PCR buffer, 0.33 uL 10mM dNTPs, 0.33 uL Ovarian cDNA, and 0.2 uL of the Pfx 50 
polymerase (Invitrogen, Carlsbad, California, USA) and 0.25 uL of both the forward and 
reverse primers for the hrDecorin gene were added to water in 10 uL final volume. The 
PCR program consisted of a denaturing step of 94°C for 2 minutes followed by 40 cycles 
of 94°C for 15 seconds, 53°C for 30 seconds, 68°C for 1 min, a final 68°C for 5 minutes, 
and a holding temperature of 4 °C. The PCR products were separated by loading product 
on a 0.7% agarose gel with 2uL 10x Orange G and 2uL 10x Sybr Green fluorescent dyes. 
The PCR product sizes were compared to a 1kb ladder (New England Biolabs, Inc., 
Ipswich, Massachusetts, USA) to estimate fragment size. The isolated band weighed 
0.080gm and the QIAEX II Agarose Gel Extraction protocol was followed as described 
in the section below. The isolated hrDecorin PCR product was measured using a 
Nanodrop spectrometer (Thermo Scientific, Wilmington, Delaware, USA). The 
concentration of 3.74 ng/uL, a 260/280 ratio of hrDecorin was 1.49, and a 260/230 ratio 
of 0.78. 
 
2.1.3 - PCR protocol for hrIFNb 
Human recombinant IFNb was amplified using a NT2D1 genomic DNA sample 
obtained from Dr. Edward Perkins. The PCR tube contained 1 uL pfx 50 PCR buffer, 
0.3uL 10mM dNTPs, 0.5 uL NT2D1 DNA, and 0.25 uL of both the forward and reverse 
primers for hrIFNb were added to water to a final volume of 10uL. The mixture was run 
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using the program as described in section above and separated using electrophoresis as 
described for hrDecorin. The isolated band weighed 0.160gm and the QIAEX II Agarose 
Gel Extraction protocol was used to isolate hrIFNb. The concentration of isolated hrIFNb 
PCR product was determined to be 12.86 ng/uL, and the product had a 260/280 ratio of 
1.32, and a 260/230 ratio of 1.32. 
 
2.1.4 - PCR protocol for hrTRAIL 
Human recombinant TRAIL was amplified from a human testicular cDNA library 
obtained from by Dr. Edward Perkins. The reaction tube contained 1.6 µL dNTPs, 0.5 µL 
testes cDNA, 0.1 µL LATaq (Takara, Shiga, Japan), 0.3 µL forward and reverse primers 
for hTRAIL, 1 µL LA Taq buffer, 1 µL betaine, and 5.2 µL dH20 for a total of 10 µL. The 
solution was run on a different PCR program that consisted of a denaturing step of 94°C 
for 2 minutes followed by 35 cycles of 94°C for 30 seconds, 54°C for 60 seconds, 68°C 
for 1 min, a final 68°C for 5 minutes, and a holding temperature of 4 °C. The products 
were run on a 1.5% agarose gel with 1 µL of 10x Sybr Green and 1 µL 10x Orange G dye 
added to each tube. The resultant bands were compared to 1kb and a low molecular 
weight ladder (New England Biolabs, Inc., Ipswich, Massachusetts, USA). Also run on 
the gel was 10 µL of the identical PCR reaction, however the contents of the tube were 
digested using 1 µL K buffer and 0.3 µL ScaI (Promega, Madison, Wisconsin, USA) 
restriction enzyme prior to electrophoresis. The digested products conformed to the 
expected band fragment sizes which indicated probable successful amplification. The 
isolated and undigested band of interest weighed 0.093gm and the QIAEX II Agarose Gel 
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Extraction protocol was followed. The purified hTRAIL PCR product was measured to 
be 12.3ng/ µL with a 260/280 ratio of 1.1. 
 
2.1.5 - QIAEX II Agarose Gel Extraction 
The QIAEXII agarose gel extraction (Qiagen, Valencia, California, USA) 
protocol was used to isolate DNA from agarose gels. The procedure began by using a 
scalpel to remove bands dyed with Sybr Safe that had undergone gel electrophoresis to 
separate DNA fragments of interest. The isolated bands were further processed by 
removing excess agarose away from the fluorescent portion of the bands. The isolated gel 
fragments were weighed to calculate the correct amount of QX1 buffer to add to the gel 
fragment. A ratio of 3 µL of QX1 to 1mg of agarose gel was added to a 1.5 mL 
microcentrifuge tube. Before adding 10uL of QIAEXII to the QX1 gel fragment solution, 
the QIAEXII was resuspended by votexing for 30 seconds. The QIAEX II, QX1, and gel 
fragment were incubated in a 50-60°C sand bath for 6 minutes while inverting and 
votexing the solution every 2 minutes. The solution was centrifuged for 30 seconds at 
13,000RPM and the supernatant was removed. The remaining pellet was washed and 
resuspended in 500 µL of buffer QX1 and recentrifuged at 13,000RPM for 30 seconds. 
The subsequent pellet was then washed twice with 500 µL PE buffer. With each wash, 
the pellet was resuspended and the solution was centrifuged at 13,000RPM for 30 
seconds. Following the second wash with PE, the pellet was air dried for 10 to 15 minutes 
or until the pellet became white. The pellet was resuspended in a two staged approach to 
yield maximum DNA collection. The first step, 20 µL of autoclaved 10mM Tris-Cl, pH 
8.5 was used to resuspend the dried pellet, the solution was votexed and centrifuged for 
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30 seconds at 13,000RPM and the supernatant was transferred to a 0.5mL 
microcentrifuge tube. The next step repeated the prior DNA extraction step replacing 20 
µL 10mM Tris-Cl with 10 µL 10 mM Tris-Cl. The two supernatants were added together 
to yield 30 µL of the isolated DNA solution. Subsequent Nanodrop readings were 
conducted to determine concentration, amount, and possible contaminants with the DNA 
extracted from agarose gel. 
 
2.1.6 – E. coli Transformation Protocol 
Competent cells were stored in -70°C freezer and used when needed. The plasmid 
DNA was placed in 50uL of 1x KCM (100mM KCl, 30mM CaCl2) in a 14mL round 
bottom tube on ice. The 50uL of competent cells were thawed on ice and mixed gently 
with the DNA and KCM mixture. This solution was kept on ice for 10 to 20 minutes. 
Following the ice incubation, the cell mixture was heat shocked at room temperature for 
10 minutes. After being heat shocked, the cells were brought up in 400 µL SOC medium. 
Cultures were then incubated at 37°C for 1 hour in a shaker at 225 RPM. A portion of the 
culture was plated using a spreader bar on LB or YT agar along with various selection 
markers. LB Kanamycin (Kan) plates were used to grow up transfected Escherichia coli 
(E. coli) with pZErO 2.1 (Invitrogen, Carlsbad, California, USA) and LB or YT 
Ampicillin (Amp) plates were used to grow up transfected E. coli with pcDNA 3.1 
(Invitrogen, Carlsbad, California, USA) and pGEM-T Easy vectors (Promega, Madison, 
Wisconsin, USA). Plates were incubated at 37°C overnight and colonies were isolated 
and expanded the following day. Plates with probable colonies containing the vector with 
the insert of interest were sealed with parafilm and placed in 4°C for storage. 
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2.1.7 - hrIFNb and hrDecorin Ligation and Transformation 
hrDecorin and hrIFNb were ligated into pZero2.1 using T4 DNA Ligase (New 
England Biolabs, Inc, Ipswich, Massachusetts, USA). pZErO 2.1, prior to its use in the 
ligation procedure, and cDNA was cut using the restriction enzyme blunt cutter EcoRV. 
Because this was a blunt end ligation, a higher insert to vector ratio was required. Each 
ligation reaction contained 5ng of cut pZErO 2.1 and 14.36 ng and 19.074 ng DNA (an 
insert:vector ratio of 8.5:1for hrIFNb and 10.4:1 for hrDecorin). 5.1 uL of hrDecorin or 
1.5 uL of hrIFNb, 1uL of digested pZero2.1, 2uL 10x Ligase buffer, 1/3 uL T4 DNA 
Ligase, and an amount of dH20 to bring the final volumes to a total of 20uL (11.56 uL for 
the hrDecorin tube and 15.16 uL for hrIFNb) were placed into a thermal cycler tube, 
ligated at room temperature for 2 hours, and subjected to 65 degrees for 10 minutes to 
heat kill T4 DNA Ligase. 5uL of each ligation mix was transformed into GC5 competent 
cells (Sigma Aldrich, Inc., St. Louis, Missouri, USA) using the transformation protocol 
listed above.  
 
2.1.8 - hrTRAIL Ligation and transformation 
The ligation of hrTRAIL into a vector was done using the PGEM-T Easy Vector 
System (Promega, Madison, Wisconsin, USA). 1.5 µL purified hTRAIL PCR product 
(12.3ng/ µL), 2.5 µL 2x rapid ligation buffer, 0.5 µL PGEM-T Easy Vector, and 0.5 µL 
T4 DNA Ligase were incubated at 4°C overnight and transformed into DH10B cells. Five 
and 10 µL of transformation mix along with 50 µL SOC were spread onto X-
gal/ampicillin LB agarose plates. From the two plates, a total of 4 colonies were selected 
as potential clones containing hrTRAIL. 
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2.1.9 - Plasmid DNA Isolation 
A 5 mL culture was grown from selected colonies from either a LB Kan agarose 
plate and placed into a LB Kan broth for pZErO 2.1 plasmid constructs or a LB Amp 
plate and placed into a LB Amp broth for pGEM-T Easy and pcDNA3.1/Hygro+ plasmid 
containing cells. These 5 mL cultures were grown overnight at 37°C. 1.5 mL of volume 
was spun down, the liquid was aspirated and an additional 1.5 mL of culture was spun 
down atop the existing pellet. The second volume was also aspirated leaving a double 
pellet of bacteria that potentially had incorporated the transformed plasmid of interest. 
The pellet was resuspended in 100 uL of lysis buffer. The lysis buffer consisted of 10mM 
Tris-HCl with a pH of 8.0, 1mM EDTA, 15% wt/vol sucrose, 2mg/mL lysozyme, 0.2 
mg/mL pancreatic RNase, and 0.1 mg/mL bovine serum albumin. The resuspended pellet 
was placed in a room temperature microcentrifuge shaker for 5 minutes. Following the 
shaking, the tubes were placed into a rack with a cover and submerged in boiling water 
for 1 minute, the rack was quickly transferred to an ice water bath for 1 minute. The tubes 
were spun at 13,000xg for 20 minutes in room temperature. Approximately 90 uL of 
supernatant was transferred to a clean microcentrifuge tube to await restriction enzyme 
digest testing to determine whether or not the correct PCR product had been inserted into 
the plasmid. 
 
2.1.10 - Plasmid Verification of hrIFNb 
Five uL of each of the 6 hrIFNb easy preps (all from the NT2D1 template library), 
isolated from cultures grown from random white colonies grown on LB plates containing 
Kan and X-gal, were digested with PstI (New England Biolabs, Inc., Ipswich, 
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Massachusetts, USA). The reactions were incubated for 2 hours at 37°C. One uL of 10X 
Orange G was added to each 10uL digestion reaction, the contents of the tubes were 
lightly vortexed and spun. Ten uL of each sample was loaded into an ethidium bromide 
(EtBr) gel for electrophoresis. The expected bands from a PstI digestion of pZErO 2.1, 
with the hrIFNb fragment inserted into the EcoRV site in the forward orientation, were 
roughly 200 and 3600bp. Band fragments measured indicate that a correct fragment had 
likely been inserted. The plasmids were regrown and purified using the Sigma Miniprep 
Plasmid Isolation Kit. Once regrown and purified, the clean pZErO 2.1 + suspected 
hrIFNb insert were digested with PstI in 10uL volumes. Digests were run on EtBr with 
1uL of Orange G dye added to each digest. Plasmids exhibiting the expected restriction 
fragment sizes were subsequently purified and sequenced to verify fragment identity. 
 
2.1.11 - Plasmid Verification of hrDecorin 
Five uL of each of the 12 hrDecorin easy preps (6 samples from ovarian and 6 
samples from brain template cDNA libraries) isolated from cultures grown from random 
white colonies grown on LB plates containing Kan and X-gal were cut using HindIII 
(New England Biolabs, Inc., Ipswich, Massachusetts, USA). The reactions were 
incubated for 2 hours at 37°C. One uL of 10X Orange G was added to each reaction and 
the contents of the tubes were lightly vortexed and spun. Ten uL of each sample was 
loaded into an EtBr gel. The expected bands from a HindIII digestion of pZErO 2.1 with 
the hrDecorin fragment inserted into the EcoRV site were roughly 850 and 3500bp if 
inserted in the forward direction (correct orientation). For clones exhibiting the expected 
and correct digestion pattern, plasmids will be regrown and purified using the cleaner 
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Genelute kit (Sigma-Aldrich, Inc., St. Louis, Missouri, USA). Once regrown and 
purified, the clean pZErO 2.1 with the suspected hrDecorin insert were again digested 
with HindIII. Digests were run on a EtBr agarose (0.7%) gel. Bands occur slightly under 
the 1kb band from the 1log ladder standard (New England Biolabs, Inc., Ipswich, 
Massachusetts, USA), resulting in a banding pattern predicted by the digestion of pZErO 
2.1 + hrDecorin. Purified plasmids were sequenced to verify and confirm fragment 
identity. 
 
2.1.12 - hrTRAIL Colony Selection 
Four colonies, labeled hrTRAIL 3.1-1 through 3.1-4 were grown in LB broth in 
the presence of ampicilin and purified using the E. coli miniprep protocol. Each sample 
was cut in separate reactions with either ScaI or EcoRI (New England Biolabs, Inc., 
Ipswich, Massachusetts, USA). For each sample, restriction enzyme digestions were 
performed in 10uL volumes. The digests were incubated for 48 hours at 37°C. The 
products were run on 0.6% agarose gel with EtBr along with the 1 kb ladder (New 
England Biolabs, Inc., Ipswich, Massachusetts, USA). Comparing the bands from the gel, 
hrTRAIL samples 3.1-3 and 3.1-4 had exhibited the proper banding pattern expected for 
a hrTRAIL insert.  
 
2.1.13 – Preparation and analysis of restriction verified fragments 
Once there was sufficient evidence that a transformed clone potentially 
incorporated the plasmid with the correct insert, a fresh culture of 4 to 5 mL was grown 
in either 2XYT or LB broth with the correct antibiotic (Kan for pZero 2.1 and Amp for 
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PGem-T Easy and pZero 3.1) and plasmid was isolated with the GenElute Plasmid 
Miniprep kit (Sigma-Aldrich, Inc., St. Louis, Missouri, USA). From the culture, 1.5 mL 
was spun at 12,000 to 13,000xg for 1 minute in a microcentrifuge tube. The supernatant 
was removed and another 1.5 mL of culture was placed atop the pellet, spun for another 
minute at 12,000 to 13,000xg. The supernatant was again removed. The double pellet was 
resuspended in 200 uL of the resuspension solution. Two hundred uL of lysis solution 
was placed into the resuspended solution and immediately inverted 6 to 8 times. Three 
hundred and fifty uL of neutralizing/binding solution was placed into the mixture before 
5 minutes had elapsed. Subsequently, the new solution was inverted 4 to 6 times. This 
solution was spun for 10 minutes at 12,000xg to 13,000xg at room temperature. During 
this time, the spin columns were inserted into the supplied microcentrifuge tubes and 
prepared by adding 500uL of column preparation solution to each column and spun for 1 
minute at 12,000xg to 13,000xg. The flow through was discarded and the cleared lysate 
from the lysed solution was transferred to the prepared column carefully to limit the 
amount of cellular debris and other precipitate that was transferred to the column. Once 
in the column, the solution was spun for 1 minute at 12,000xg to 13,000xg. The flow 
through was discarded and 750 uL of wash solution was placed into the column and the 
tube was spun again for 1 minute at 12,000xg to 13,000xg. Again, the flow through was 
discarded and the column was spun again for 2 minutes at 12,000xg to 13,000xg to 
ensure that all of the wash solution was spun out of the column. The dry column was 
placed into a clean tube and 100 uL of RNAse and DNase free H20 was placed into the 
column. The tube was spun for 1 minute at 12,000xg to 13,000xg and the flow through 
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contained the eluted plasmid. The isolated plasmid was placed on ice and measured using 
the Nanodrop spectrometer.  
Table 2- DNA readings following a Sigma Miniprep Plasmid Isolation for hrDecorin and 
hrIFNb 
Reading ng/uL Ave ng/uL 260/280 Ave 260/280 260/230 Ave 260/230
hrDecorin 1 1 96.25 94.85 1.8 1.81 1.86 1.835
2 93.45 1.82 1.81
hrDecorin 2 1 91.75 90.415 1.84 1.85 1.91 1.92
2 89.08 1.86 1.93
hrIFNb 21 1 120.2 119.29 1.9 1.875 2 2
2 118.38 1.85 2
hrIFNb 24 1 97.18 99.88 1.87 1.865 1.97 1.85
2 102.58 1.86 1.73
 
 
 
2.1.14 - Purifying easyprep isolations using Qiagen miniprep purification protocol from 
“other methods” 
The easy miniprep isolations of the potentially correct ligated vector+insert 
hrTRAIL 3.1-3 and hrTRAIL 3.1-4 that needed to be purified more completely for use in 
the DNA sequencer were estimated to have a volume of 90uL. The Qiagen protocol 
required a volume of PB solution 5X more than the purified plasmid volume. The 
samples were then placed into the prepared spin columns and the protocol was continued. 
The resultant concentration and purity of the DNA is indicated in Table 3. These samples 
were then sequenced using the CEQ 8000 Genetic Analysis System (Beckman Coulter, 
Inc., Brea, California, USA). 
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Table 3- DNA readings following a Sigma Miniprep Plasmid Isolation for hrTRAIL 
ng/uL Average ng/uL 260/280 260/230
TRAIL 3.1-3 202 206 1.9 3.05
TRAIL 3.1-3 2nd read 210 1.9 2.3
TRAIL 3.1-4 274 261.5 1.83 2.27
TRAIL 3.1-4 2nd read 249 1.88 2.29
 
 
 
2.1.15 - Sequencing of Isolated Constructs 
The purified GenElute plasmid miniprep constructs were sequenced using a 
CEQ8000 (Beckman Coulter, Inc., Brea, California, USA). The presence of human 
recombinant factor inserts within a plasmid was verified by using SP6, M13 reverse, and 
M13 forward primers. The sequencing primer binding sites occur flanking the insert on 
pZErO-2.1 and pGEM T Easy. The reagents and protocol were obtained from The 
Beckman Coulter Genome Lab Dye Terminator Cycle Sequencing (DTCS) Quick Start 
Kit. Sequencing primers were diluted to 1.6uM prior to beginning the experiments. One 
hundred and thirty ng of plasmid DNA (Table 1)was brought up to a final volume of 6 µL 
with molecular grade H2O in a thermalcycle tube and treated at 96°C for 1 minute. 
Following DNA treatment, 8 µL of Master Mix, 2 µL of SP6/M13 Rev primer or 2 µL of 
M13For, and 4 µL of molecular grade H2O were added to each tube. Tubes were votexed 
and the contents were pooled by brief centrifugation. The tubes were run on the PCR 
program CEQSER. This program consisted of 31 cycles of 96°C for 20 seconds, 50°C for 
20 seconds, 60°C for 4 min, and a holding temperature of 4°C. Following the PCR 
amplification, the amplified DNA solutions were pipetted into a 0.5mL tube containing a 
stop solution consisting of 2 µL of 3M sodium acetate, 2 µL 100mM Na2-EDTA, and 1 
µL of glycogen per sample. The tubes were then vortexed thoroughly and the contents 
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were lightly spun. In a refrigerated environment, 60 µL of ice cold 95% ethanol was 
placed into each tube, mixed thoroughly, and spun at 14,000 RPM for 15 minutes. The 
supernatant was removed and the pellet was washed 2 times with 200 µL 70% ethanol. 
Special care was taken to not dislodge the pellet. Each wash was completed by spinning 
the pellet and 70% ethanol at 14,000RPM at 4°C for 5 minutes and discarding the 
supernatant. After the final wash, the pellet was spun at max speed for 1 minute to 
remove any residual supernatant. At room temperature, the tube caps were left open to 
allow evaporation of the remaining ethanol. Following complete evaporation, the dried 
pellets were resuspended into 40 µL of the sample loading solution. The solution was 
allowed to sit for 10 minutes, and then the solution and pellet were votexed and spun. The 
sample plate was loaded with 40 µL along topped with one drop of mineral oil. The 
buffer plate was loaded with 10 drops of separation buffer to each well in the buffer plate. 
Both the sample and buffer plates were then loaded into the CEQ8000. The sequencer 
was run in “LFRc mode” and the following options were selected options menu. In the 
analysis section, the perform analysis box was checked. In the export section, the export 
data box was selected and the export options were edited to ensure that raw data, results 
data, results output, quality parameters, alignment results, and alignment accuracy boxes 
were checked to ensure proper data collection. These settings were saved and the output 
file was assigned a name corresponding to the DNA sequence project of interest. Once 
the file was saved, capillary array and the gel cartridge were installed, manifold purge 
was performed, and the wetting tray had been filled, the trays were loaded and samples 
were sequenced. The output was analyzed using several methods, but the primary 
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sequences were analyzed using Vector NTI versions 10 and 11 (Invitrogen, Carlsbad, 
California, USA) to align raw sequences to NCBI reference sequences.  
 
2.1.16 - Strategy of Isolating hrDecorin inserts from pZErO 2.1 
Following sequence verification, pZErO 2.1 hrDecorin 1 and pZErO 2.1 
hrDecorin 2 were double digested with BamHI (New England Biolabs, Inc.) and XhoI 
(Promega, Inc.). Digestions were done in a 37°C incubator. 
 
2.1.17 - Strategy of Isolating hrIFNb inserts from pZErO 2.1 
Following sequence verification, pZErO 2.1 hrIFNb21 and pZErO 2.1 hrIFNb24 
were double digested with HindIII and XbaI (New England Biolabs, Inc.). Digestions 
were done in a 37°C incubator.  
 
2.1.18 - Double Digest Fragment Isolation 
Double digests of pZErO 2.1 hrDecorin and pZErO 2.1 hrIFNb were designed to 
isolate the human recombinant genes of interest from the plasmid pZErO 2.1. The 
digested products were run on an agarose gel following loading with Sybr Safe. The 
Qiaex II gel extraction protocol was performed on the 4 bands (2 bands for hrDecorin and 
2 bands for hrIFNb) containing the genes of interest. pcDNA 3.1/Hygro+ (Invitrogen, 
Carlsbad, California, USA) was also double digested in a manner that would leave sticky 
ends to facilitate proper incorporation and ligation of the gene of interest into pcDNA 3.1. 
These plasmid digests were separated using electrophoresis on agarose gel following 
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addition of Sybr Safe. The fragments were isolated from the gel and the DNA was 
extracted using the Qiaex II gel extraction protocol.  
 
2.1.19 - Antarctic Phosphatase 
pcDNA3.1 Hygro+ (Invitrogen, Carlsbad, California, USA) following double 
digestion in preparation for the insertion of human recombinant factors was treated with 
Antarctic Phosphatase (New England Biolabs, Inc., Ipswich, Massachusetts, USA) to 
remove 5’ phosphates on the free ends of the cleaved plasmid inhibiting the religation to 
itself without the incorporation of the human recombinant inserts.  
 
2.1.20 - Double Digest of pcDNA 3.1 for hrDecorin 
pcDNA 3.1/Hygro+ (Invitrogen, Carlsbad, California, USA) was cut using XhoI 
(Promega, Madison, Wisconsin, USA), and BamHI (New England Biolabs, Inc., Ipswich, 
Massachusetts, USA). The digests were left overnight at 37°C to ensure the vector was 
completely digested. Following the digest, 1uL of 10X Antarctic Phosphatase buffer and 
1 uL of Antarctic Phosphatase were added to the overnight digests to remove the free 
phosphates on the cut plasmid to prevent religation. The solution was run on the thermal 
cycler program PWANTPHO. This program consisted of 37°C for 15 minutes followed 
by 65°C for 5 minutes. Sybr Safe and Orange G were added to the digest and the 
reactions were run on an agarose gel. The resultant band was isolated and the DNA was 
extracted using the Qiaex II gel extraction protocol.  
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2.1.21 - Double Digest of pcDNA 3.1 for hrIFNb 
pcDNA 3.1 was cut using HindIII and NheI (New England Biolabs, Inc., Ipswich, 
Massachusetts, USA) in a 10uL final volume. The digests were left overnight at 37°C to 
ensure the vector was completely digested. Following the digest, the vector was treated 
with Antartic Phosphase (New England Biolabs, Inc., Ipswich, Massachusetts, USA) to 
prevent vector religation. The reaction was carried out using the thermal cycler program 
PWANTPHO. Sybr Safe and Orange G were added to the digest and the sample was 
subjected to agarose gel electrophoresis. The resultant vector band was isolated and the 
DNA was extracted using the Qiaex II gel extraction protocol.  
 
2.1.22 - Ligation of Double Digest hrDecorin and hrIFNb 
hrDecorin and hr IFNb were ligated into cut pcDNA 3.1 plasmids using T4 DNA 
Ligase (New England Biolabs, Inc., Ipswich, Massachusetts, USA). The insert to vector 
ratio was 10 to 1, 9 to 1, 14.5 to 1 and 16.5 to 1 for hrDecorin1, hrDecorin2, hrIFNb 21, 
and hrIFNb 24b respectively. hrDecorin1 and hrDecorin2 were ligated into the digested 
pcDNA3.1 digested specifically for the incorporation of hrDecorin fragments. hrIFNb21 
and hrIFNb24 were ligated into the digested pcDNA3.1 digested specifically for 
directional cloning of the hrIFNb fragments. Control ligations for pcDNA 3.1 cut for 
hrDecorin and pcDNA 3.1 cut for hrIFNb without human recombinant DNA were 
conducted using the same quantity as the ligation without human recombinant DNA. All 
ligations were performed in 10 uL final volume. Three uL of each ligation were 
transformed using the modified E. coli transformation protocol. Four colonies from 
hrDecorin1, 3 colonies from hrIFNb21, and 4 colonies from hrIFN24 were grown in LB 
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Amp cultures overnight and the plasmid DNA was isolated using the Sigma Miniprep 
Plasmid Isolation Kit (Sigma-Aldrich, Inc., St. Louis, Missouri, USA).  
 
 
Table 4- Values from the various parameters for DNA isolation 
band weight QX1 Buffer Vol ng/uL 260/280 260/230
hrDecorin 1 DD 92 mg 276 mL 5.97 1.25 0.76
hrDecorin 2 DD 94 mg 282 mL 5.24 1.27 0.8
hrIFNb 21 DD 116 mg 348 mL 19.72 1.4 0.84
hrIFNb 24 DD 120 mg 360 mL 10.98 1.46 0.79
pcDNA 3.1 - DCN cut 88 mg 264 mL 5.9 1.65 0.65
pcDNA 3.1 - IFNb cut 114 mg 342 mL 12.83 1.41 0.6
 
 
 
2.1.23 - Digest Verification of hrDecorin and hrIFNb Insertion into pcDNA3.1 
The hrDecorin samples (5 uL of each) were digested with BamHI (New England 
Biolabs, Inc., Ipswich, Massachusetts, USA) and XhoI (Promega, Madison, Wisconsin, 
USA) in 10uL final volume. hrIFNb samples (5 uL of each) were digested with HindIII 
and NheI (New England Biolabs, Inc., Ipswich, Massachusetts, USA) in a 10uL final 
volume. All digestions were carried out overnight at 37°C. Digestion of isolated 
pcDNA3.1+ insert and insert free uncut pcDNA3.1/Hygro+ were conducted to verify the 
correct insertion of the fragments into the pcDNA3.1 plasmid. The uncut naive pcDNA 
3.1/Hygro+ and pcDNA3.1 hrDecorin1 isolated plasmid were digested with the HindIII 
enzyme. The uncut naive pcDNA 3.1/Hygro+ and pcDNA3.1 IFNb21 and pcDNA3.1 
IFNb24 isolated plasmids were digested with the PstI enzyme. The agarose gel bands 
representing all of the digests were compared with undigested, uncut, and naive pcDNA 
3.1/Hygro+ vector and the 1kb ladder (New England Biolabs, Inc., Ipswich, 
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Massachusetts, USA). Both hrDecorin and hrIFNb containing vectors exhibited the 
expected band fragments. 
 
2.1.24 - Transformation of Restriction Verified Fragments 
Aliquots (0.5uL) of pcDNA3.1 + hrDecorin1, pcDNA3.1 + hrIFNb 21, or 
pcDNA3.1 + hrIFNb 24 were transformed into GC5 cells using the modified E. coli 
transformation protocol. One hundred uL of each transformation mix was plated on 
LB/Amp plates. A colony was isolated from each transformation plate, the colony was 
grown up and stored in 50% glycerol and stored in a -70°C freezer.  
  
2.1.25 - TRAIL Construction from Sequenced Fragments Containing Errors 
The sequence results for hrTRAIL 3.1-3 and hrTRAIL 3.1-4 both displayed a few 
DNA sequence errors. The sample hrTRAIL 3.1-3 was halted because the errors in 
hrTRAIL 3.1-4 contained fewer sequence errors. The 5’ end of hrTRAIL 3.1-4 was 
identical to the reference sequence obtained from the NBCI gene sequence database 
(www.ncbi.nlm.gov). The 3’ end of hrTRAIL 3.1-4 had problems within the primer 
region and a single nucleotide polymorphism in a “wobble” base position in an amino 
acid directly adjacent to the primer leading to a silent mutation. hrTRAIL 3.1-4 was used 
as the template for amplification. A PCR reaction consisting of 1.6uL 10mM dNTPs, 5ng 
hrTRAIL 2.1-4, 0.1 uL LATaq (5UuL: Takara, Shiga, Japan), 0.3uL hrTRAIL forward 
primer (10 uM), 0.3uL hrTRAIL reverse primer (10 uM), 1uL LATaq Buffer, 1uL 
Betaine, 5.2uL dH2O was performed using the PCR program “Paul 2.” Following the 
PCR amplification, the DNA was electrophoresed on an agarose gel using 1uL of Sybr 
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Safe added directly to the PCR sample. The expected 850 bp bands were isolated. The 
DNA was isolated using the Qiaex gel extraction protocol (Qiagen, Valencia, California, 
USA). The first gel fragment weighed 246 mg, requiring 738 uL of QX1 solution to be 
used. The second gel fragment weighed 91 mg, requiring 273 uL of QX1 solution to be 
used. The remainder of the protocol follows the Qiaex II Agarose Gel Extraction protocol 
previously listed in this manuscript. The concentration and purity values for the isolated 
DNA are listed on Table 5. 
 
Table 5- DNA Values for Isolated hrTRAIL 
ng/uL 260/280 260/230
hrTRAIL 3.2a 38.9 2.05 1.88
hrTRAIL 3.2a 2nd elution 9.89 2.31 1.56
hrTRAIL 3.2b 39.6 1.9 1.94
hrTRAIL 3.2b 2nd elution 13.8 1.62 1.05
 
 
 
The new PCR product was ligated into the pGEM-T Easy Vector System 
(Promega, Madison, Wisconsin, USA) using 0.56uL Purified hrTRAIL v3.2a or 
hrTRAIL v3.2b, 2.5uL 2X rapid ligation buffer, 0.5 uL pGEM-T Easy Vector, 0.5uL T4 
DNA Ligase, and 0.94uL dH2O. The contents of each tube were briefly votexed and spun 
to ensure proper mixing of all elements. The tubes were incubated overnight at 4°C. The 
ligation mixes were transformed using the One Shot Top 10 kit (Invitrogen, Carlsbad, 
California, USA). One uL of hrTRAIL v3.2a or hrTRAIL v3.2b was transferred into 1 
vial of Top10 cells that had thawed on ice and was tapped to gently mix the DNA. The 
mixture was incubated on ice for 30 minutes. The cells were then incubated for 30 
seconds in a 42°C water bath and immediately placed back in the ice bath for 2 additional 
minutes. Two hundred and fifty uL of SOC media was placed into the tubes of both 
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pGEM-T Easy + hrTRAIL v3.2a and pGEM-T Easy + hrTRAIL v3.2b. Both tubes were 
then placed on a shaking incubator at 37°C for 60 minutes. One hundred uL of both 
hrTRAIL v3.2a and hrTRAIL v3.2b were plated on LB AMP plates and grown for 20 
hours at 37°C. Four colonies were selected from the hrTRAIL v3.2a plate and six 
colonies were selected from the hrTRAIL 3.2b plate and expanded in LB+AMP broth. 
The plasmids were isolated using the Easy Quick Prep protocol. The plasmids were 
digested using either EcoRI (New England Biolabs, Inc., Ipswich, Massachusetts, USA) 
or ScaI (Promega, Madison, Wisconsin, USA) on the hrTRAIL plasmids in 10 uL final 
volumes. The digests were run on an EtBr agarose gel. From the digests, samples 3.2 A1 
and 3.2 A2 conferred the expected fragment sizes. The hrTRAIL v3.2a1 and 3.2 a2 were 
transformed into GC5 cells. Four colonies were selected from both hrTRAIL v3.2A1 and 
v3.2A2 and identified as hrTRAIL v3.2A1-1 through 4 and hrTRAIL v3.2A2-1 through 
4. The colonies were grown in LB AMP and the plasmids were purified using the Sigma 
Miniprep Plasmid Isolation Kit (Sigma-Aldrich, Inc. St. Louis, Missouri, USA). The 
same EcoRI and ScaI digests were conducted and all samples exhibited proper band 
fragment sizes. Samples hrTRAIL v3.2A1-1 and hrTRAIL v3.2A2-1 were saved and 
sequenced. pGEM-T Easy hrTRAIL 3.2A1-1 was measured at a concentration of 
43.6ng/uL and pGEM-T Easy  hrTRAIL 3.2A2-1 was measured at a concentration of 
48.6 ng/uL. During the DNA sequence process 130ng of each hrTRAIL plasmid was 
used. The samples were sequenced as described in Sequencing of Isolated Constructs 
section (see above).  Sequencing results indicated that the 5’ end of hrTRAIL v3.2A1-1 
was an exact match however 5’ hrTRAIL v3.2A2-1 had two errors in comparison to the 
reference code. The 3’ end of hrTRAIL v3.2A2-1 differed from the reference sequence 
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by encoding a different stop codon and a wobble position change for the 8th codon or 7th 
terminal amino acid from the end of the sequence. This single nucleotide polymorphism 
matched NCBI reference sequence rs1131532 in the database. From this point, the 
strategy was to splice the 2 correct portions of the gene to yield one complete and correct 
version of the gene.  
To carry out the ligation of the 5’ region of hrTRAIL v3.2A1-1 with the 3’ region 
of hrTRAIL v3.2A2-1, the PstI site within the hrTRAIL gene along with the PstI site on 
the pGEM-T Easy, was chosen for correcting the sequence errors. Digesting hrTRAIL 
v3.2A1-1 with PstI (New England Biolabs, Inc., Ipswich, Massachusetts, USA) yielded 2 
fragments, one fragment containing the correct 5’ portion of the hrTRAIL gene 
measuring roughly 100bp and the other fragment containing plasmid vector backbone 
along with nearly 750bp representing the remaining 3’ portion of the gene. Digesting 
hrTRAIL v3.2A2-1 with PstI yielded 2 fragments, one fragment containing the correct 3’ 
portion of the hrTRAIL gene along with the complete pGEM-T Easy and the other 
fragment was roughly 100bp containing the incorrect 5’ region. The PstI  digests were 
done overnight at 37°C to ensure complete digestion. The completed digestion of the 
vector containing the correct 3’ end of the gene in pGEM-T Easy was treated with 
Antarctic Phosphatase (New England Biolabs, Inc., Ipswich, Massachusetts, USA) to 
prevent religation. The reaction was carried out for 30 minutes and following the 
phosphatase reaction, 2.5uL of Sybr Safe and 2.5uL of Orange G loading gel were added 
to the digest. The products were evaluated on an agarose gel. The resultant band running 
near 4kb was isolated.  
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Because the 5’ fragment from the PstI digestion of hrTRAIL v3.2A1-1 was so 
small in relation to the size of the other fragment created from the PstI digestion, the 
current DNA concentration was not high enough to yield a high amount of the 5’ region 
of hrTRAIL v3.2A1-1, the original hrTRAILv3.21-1 was retransformed into GC5 cells to 
purify larger and higher concentrated amounts of this DNA. Two colonies were isolated 
from the retransformation of hrTRAIL v3.2A1-1. After performing the Sigma Miniprep 
Plasmid isolation, a higher concentration of plasmid was isolated. The concentration of 
hrTRAIL v3.2A1-1 DNA is listed in Table 6. 
 
Table 6- Purified DNA plasmid values from the sequence verified TRAIL v3.2A1-1 
regrown cultures 
 ng/uL 260/280 260/230 
TRAIL v3.2A1-1 
Regrow 1 
140 1.92 2.37 
TRAIL v3.2A1-1 
Regrow 2 
136 1.90 2.42 
 
 
A large amount of higher concentrated hrTRAIL v3.2A1-1 from both purified 
colonies was cut to isolate 100bp PstI fragment containing the correct 5’ region. Eighty 
uL of either hrTRAIL v3.2A1-1 R1 or hrTRAIL v3.2A1-1 R2 (R= regrown plasmid) 
containing v3.2A1-1 were digested with PstI overnight. The Orange G loading buffer and 
Sybr Safe were added to each digest, and each digest was split into two lanes due to 
volume. The digests were run along with a 1kb and a 100bp ladder (New England 
Biolabs, Inc., Ipswich, Massachusetts, USA). Two distinct bands were seen at near 100 
bp and several thousand bp. The 100bp band for all four lanes was isolated, purified, and 
quantified using the Nanodrop. The results for the Nanodrop are listed in Table 7. 
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Table 7- DNA values for ATG fragments from sequence verified hrTRAIL v3.2A1-1 
regrown colonies 
 ng/uL 260/280 260/230 
ATG fragment from R1-1 7.76 1.55 0.74 
ATG fragment from R1-2 4.10 1.74 0.62 
ATG fragment from R2-1 9.08 1.90 0.76 
ATG fragment from R1-2 9.03 1.26 0.51 
 
The 3’ region of hrTRAIL v3.2A2-1, containing the complete pGEM-T Easy Vector, was 
ligated with the 5’ segment isolated from hrTRAIL v3.2A1-1 using T4 DNA Ligase 
(New England Biolabs, Inc., Ipswich, Massachusetts, USA) in 10 uL final volume. One 
point one uL (10.6ng) of digested hrTRAIL v3.2A2-1 (containing plasmid and 3’ region), 
1uL (9.08ng) of the hrTRAIL v3.2A1-1 R2-1 fragment were used for ligations. The 
ligation control used 1.1uL (10.6ng) of digested hrTRAIL v3.2A2-1 (containing plasmid 
and 3’ region) only. The ligations were run using the thermal cycler program “LigKill.” 
Three uL of the ligation and the ligation control were transformed into 50uL of GC5 
competent cells.  
 Twenty five uL of the transformation mix was plated on LB Amp plates. Colony 
PCR was conducted on 24 colonies that had grown on the LB Amp plates. Using a 10uL 
pipet tip, a colony was picked off the plate and the tip was rubbed into the bottom of a 
PCR tube, resulting in plasmid DNA ready for amplification. In addition, the tips were 
each placed into LB broth with Amp to expand the selected colonies that had been picked 
from the ligation transformation plate. In each PCR tube, 5 uL of 2x GoTaq mix 
(Promega, Madison, Wisconsin, USA), 0.5uL hrTRAIL For primer (10 uM), 0.5uL 
hrTRAIL Rev Primer (10 uM) in a final volume of 10 uL. The PCR reactions were 
carried out using the “Paul2” PCR program and the samples were loaded on an EtBr 
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agarose gel and subjected to electrophoresis. hrTRAIL v3.2A1/A2 samples 1, 4, 5, 7, 10, 
11, 15, 17, and 18 all displayed DNA products occurring near hrTRAIL’s expected 846 
bps. These correct plasmid samples were isolated from the overnight cultures. Only the 
cultures from hrTRAIL 3.2 A1/A2 1 and hrTRAIL 3.2 A1/A2 4 were purified using the 
Sigma Miniprep Plasmid Isolation protocol. These two samples were sequenced to verify 
a proper ligation of the two previously verified portions of the hrTRAIL gene.  One 
hundred and thirty ng of both hrTRAIL 3.2 A1/A2 1 and hrTRAIL 3.2 A1/A2 4 were 
sequenced using the sequencing protocol described previously. hrTRAIL 3.2A1/A2 1 was 
found to match the reference sequence for hTRAIL.  
hrTRAIL 3.2 A1/A2 1was removed from pGEM-T Easy by a double digest of 
SpeI and ApaI restriction enzymes (New England Biolabs, Inc., Ipswich, Massachusetts, 
USA). pcDNA 3.1/Hygro+ was cut using NheI and ApaI restriction enzymes (New 
England Biolabs, Inc., Ipswich, Massachusetts, USA). The overhang created from the 
SpeI digest of pGEM-T Easy hrTRAIL v3.2 A1/A2 4 was compatible with the overhang 
created from a NheI digest of pcDNA3.1/Hygro+. One uL of pcDNA 3.1/Hygro+ vector 
was digested using NheI and ApaI in 10 uL final volume. Five uL of pGEM-T Easy 
hrTRAIL v3.1 A1/A2 1 was digested using ApaI and SpeI in a 10uL final volume. The 
digests were run with 1uL Orange G loading dye and 1uL Sybr Safe. The hrTRAIL digest 
yielded two fragments, one fragment contained hrTRAIL and the other band contained 
pGEM-T Easy (vector backbone). The pcDNA3.1/Hygro+ digest contained a single band 
representing the linearized plasmid. The DNA in the gel fragments was isolated using the 
QiaexII DNA gel extraction kit (Qiagen, Valencia, California, USA). Spectrophotometric 
results are shown in Table 8. 
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Table 8- DNA values for digested and isolated hrTRAIL and pcDNA3.1/Hygro+ from 
agarose gel 
Double Digested DNA ng/uL 260/230 260/280
hrTRAIL 3.2 A1/A2 1 8.66 1.2 1.78
pcDNA 3.1/Hygro+ 25.5 0.76 1.64
 
 
 
The cut vector and isolated hrTRAIL were ligated using T4 DNA Ligase. The 
control ligation consisted of cut pcDNA3.1/Hygro+ vector alone. The ligation and control 
were ligated using the “LigKill” program as described previously. The ligation samples 
were transformed into 50uL of GC5 competent cells using 3uL of each ligation following 
the modified E. coli transformation protocol. Six colonies were isolated, grown overnight 
in LB Amp broth, and the plasmids were purified using the Sigma Miniprep Plasmid 
Isolation Kit. The plasmids were verified by performing a PstI digestion comparing the 
pcDNA3.1 hTRAIL v3.2 A1/A2 1 ligation transformations with cut and uncut pcDNA 
3.1 vectors. All of the plasmid isolates appears to have correctly inserted the hrTRAIL 
fragment into the pcDNA 3.1/Hygro+ vector. The GC5 culture transformed with the 
plasmid containing the pcDNA3.1 hTRAIL v3.2 A1/A2 1 colony 1 was expanded and 
stored as the culture containing the mammalian expression vector with hrTRAIL ligated 
into it.  
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2.2 – Experimental Protocol using Sequence Verified DNA Sequences 
 
2.2.1 - Media Preparation, Cancer Cells, Splitting of Cells, and Cell Culture Management 
DMEM media was prepared by pipetting 50mL of Fetal Clone 3 (FC3: Thermo 
Fisher Scientific, Waltham, Massachusetts, USA), 5mL Glutamax (Invitrogen, Carlsbad, 
California, USA), and 5mL of 100X penicillin plus streptomycin stock (Invitrogen, 
Carlsbad, California, USA) into 500mL of DMEM. 50/50 is a media mixture consisting 
of 50 percent F12 (Hyclone, Inc.) and 50 percent DMEM. Two hundred mL of the 50/50 
media was made using 100mL of enriched DMEM with antibiotics, 90mL of F12 media, 
10mL FC3, 1mL of 100X penicillin and streptomycin stock, and 0.5mL Glutamax. The 
cancer cell lines used in this study were: MDA-MB-231 obtained from ATCC (Manassas, 
VA), UMD227 obtained from the Rose-Hellekant Laboratory (Duluth, MN), Hs578T 
obtained from ATCC, WM793 obtained from Meenhard Herlyn Laboratory 
(Philadelphia, PA), 4T1 obtained from ATCC, and MCF-7 obtained from ATCC. When 
culturing cells in 10cm dishes, 1.5mL of trypsin (Invitrogen, Carlsbad, California, USA) 
was used to remove cells from the dish, 4mL of media was used to neutralize trypsin, and 
10mL of media was used to culture the cells. With 6cm dishes, 500uL trypsin was used, 
1.5mL of media was used to neutralize trypsin, and 5mL of media was used to culture 
cells in 6cm dishes. When cells were removed from a single well in a 24 well plate, 125 
µL trypsin was used and 375 µL of media was used to neutralize the trypsin.  
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2.2.2 - Cell Counting 
Cells of interest that need to be counted were first trypsinized, spun, and 
resuspended in 1mL of 50/50 culture media. Ten µL of suspended cells were pipette into 
a 1.5 microcentrifuge tube along with 40 µL of media and 50 µL of trypan blue (0.4% 
solution, Invitrogen, Carlsbad, California, USA). The tube was then votexed and 10 µL of 
the mixture was plated onto a hemocytometer. The four corners were counted and added 
together, multiplied by the dilution factor (10x), and multiplied by 2500. The resulting 
value indicates the number of cells per mL.  
 
2.2.3 - LTX Transfectamine of CHO cells in 10 cm plates 
One day before the cells were transfected, CHO-K1 cells (ATCC, Manassas, 
Virginia, USA) were trypsinized and counted. Cell passages were kept below 30 to lower 
the possibility that the cells would diverge from the parent population. To achieve a cell 
density of 60 to 80% confluency after 24 hours of growth, 1 to 2x106 cells were plated 
the previous day. Prior to the transfection, the complete media was replaced with 8mL of 
50/50 media lacking antibiotics and serum. In a 15mL tube, 2 mL of 50/50 media lacking 
antibiotics and serum were added. 10ug of DNA isolated from the Sigma Midiprep kit 
was pipetted into the 2mL of media. 10 µL of resuspended PLUS Reagent (Invitrogen, 
Carlsbad, California, USA) was added to the media/DNA mixture, mixed gently, and the 
mixture was incubated for five minutes at room temperature. Following the incubation, 
25 µL of a resuspended Lipofectamine LTX (Invitrogen, Carlsbad, California, USA) was 
pipetteted into the PLUS/DNA complex, mixed gently through inversion, and incubated 
for 30 minutes at room temperature. Following the incubation period, the tubes were spun 
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down briefly to pool the samples. The media along with the DNA, LTX, and Plus 
reagents, were pipetted into the 10cm dishes containing CHO-K1 cells with 8mL of 50/50 
media lacking antibiotics and serum. The cells were gently rocked back and forth several 
times to facilitate proper and even distribution of the DNA complexes. The dishes were 
placed back into the 37°C incubator 5% CO2 for 6 hours. Following 6 hours of incubation 
time, the transfection media was removed and 10mL of complete growth media was 
placed back on the transfected CHO-K1 cells. Following 42 hours, the media that had 
been conditioned by the transfected CHO-K1 was collected. The collected media was 
spun at 1400RPM for 7.5 minutes. The conditioned media was removed, placed into a 
clean tube, and the pellet was left undisturbed. The media was enriched with 300 µL of 
FC3 and 50 µL of Glutamax per 10mL of conditioned media. The conditioned media was 
immediately placed onto the cells of interest and the remainder of the conditioned media 
was stored in 4°C. 
 
2.2.4 - Sulforhodamine B Assay 
Individual wells that were analyzed via SRB method, were washed with 1mL of 
1% PBS two times after growth media had been removed. Following a proper washing, 
the cells were allowed to dry for 24 hours to ensure a complete desiccation. To a dry 24 
well dish being processed, 300 µL of 0.5% sulfurhodamine B (Sigma-Aldrich, Inc., St. 
Louis, Missouri, USA) in 1% acetic acid was placed in each well. The sulforhodamine B 
was swirled and incubated at 37C for at least 45 minutes. The sulforhodamine B was 
emptied from the plate and was washed 3 times with 1% acetic acid to remove excess 
stain. The plates were allowed to dry completely and were stored in a dark environment. 
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One mL 10mM Tris pH10 was added to each dried well in a 24 well plate and placed on 
a plate rocker for 30 minutes to facilitate complete release of the sulforhodamine dye. 
One hundred µL of the dye was transferred to a well on a 96 well plate and measured at 
540nm. For wells that had reached confluency, a 1:10 dilution was made to prevent an 
incorrect reading due to limited range of the plate readers accuracy. 
 
2.2.5 - R&D Quantikine Human TRAIL ELISA 
The expression of human recombinant TRAIL in conditioned media that had been 
manufactured by CHO-K1 cells (ATCC, Manassas, Virginia, USA) was measured using 
the Quantikine ELISA kit (R&D Systems, Minneapolis, Minnesota, USA). Samples were 
obtained from hrTRAIL conditioned media, fresh media, media obtained from CHO 
cultures, and green fluorescent protein (GFP) conditioned media. Dilutions of 1:1 and 1:9 
were utilized to ensure the detection values coincided within the standard curve for 
proper calculation of TRAIL concentration in media types. The standard curve was 
created by reconstituting the TRAIL standard in 1.0mL DNase/RNase free H2O. This 
reconstituted standard represents a concentration of 10,000pg/mL. Because the hrTRAIL 
analysis involves cell culture supernate, 1x calibrator diluent RD5-33 was prepared by 
diluting 5mL of the calibrator diluent RD5-33 concentrate with 15mL DNase/RNase 
H2O. Nine hundred uL 1x RD5-33 was placed in the 100pg/mL tube and 500uL 1x RD5-
33 was pipette into the remainder microcentrifuge tubes used in making the standards. 
One hundred µL from the 10,000pg/mL TRAIL standard was pipette into the 100pg/mL 
tube that contained 900 µL 1x RD5-33. The contents were votexed and 500 µL of this 
solution was pipette into the 500pg/mL tube. A two-fold serial dilution was carried out 
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until 15.6pg/mL was achieved.  In each well 100 µL of assay diluent RD1S is placed into 
each well being used in both standard and sample wells. Fifty µL of a standard, sample, 
or a diluted sample is pipette into a corresponding well. An adhesive cover was applied to 
ensure that wells would not contaminate adjacent wells and the plate was placed on a 
horizontal orbital microplate shaker set at 500 RPM for 2 hours. Each well was emptied 
by shaking the contents out of the wells and washed by pipetting in 400 µL of wash 
buffer 4 times. Each wash phase was completed by shaking the 400 µL wash buffer out, 
and lightly hitting the plate flat on a dry paper towel ensuring maximum removal of wash 
buffer. Two hundred µL of TRAIL conjugate was added to each well and a new adhesive 
cover was attached to prevent cross well contamination. The plate was put back on the 
horizontal orbital microplate shaker for 2 hours at 500RPM. The wash step as previously 
described was repeated with a total of 4 additional washes. The substrate solution was 
mixed 5 minutes before being used and was added in a 1:1 ratio of solution A and 
solution B. Two hundred µL of this A+B substrate solution was pipetted into each well 
and allowed to incubate for 30 minutes at room temperature in a light protected 
environment. Following 30 minute incubation, 50 µL of the stop solution was put in each 
well and mixed gently for 5 minutes by gentile tapping, ensuring proper and thorough 
mixing. It was observed that the more TRAIL in a well resulted in longer time for an 
effective mixing of the stop solution. Premature reading without proper mixture of the 
stop solution resulted in a well consisting of both blue and yellow conditions, mixing 
must continue until a solid yellow persists in each well. Within 30 minutes of placing the 
stop solution into each well, the plate was read. The plate was read at 450nm on a 
SpectraMax plate reader (Molecular Devices, Sunnyvale, California, USA). To correct 
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for the plate, a 540nm reading was also taken and this value was subtracted from the 
450nm reading. The subsequent value represents the absorbance accounting for the plate 
imperfections. Microsoft Excel was used to form a fit line from the standard values and 
for statistical analysis. The unknowns were compared to the standard fit line to determine 
how much hTRAIL exists in a particular sample.  
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Chapter 3: Results 
3.1 - Sequence Verified plasmids 
hrTRAIL, hrIFNb, and hrDecorin genes were amplified into plasmids and the 
sequences were verified via DNA sequencing (Appendix A). Once verified, the genes 
were ligated into the mammalian expression vector pcDNA 3.1/Hygro+. The proper gene 
orientation and gene product were verified by restriction enzyme digestion. 
 
3.2 - MDA-MB 231, MCF-7, and WM793 cells are susceptible to the apoptotic 
effects of commercially available TRAIL 
A 24 well plate was seeded with WM793, MDA-MB-231, or MCF-7 cells using 
the 50:50 media as described in the Materials and Methods. WM793, MDA-MB-231, and 
MCF-7 cells were shown to be susceptible to apoptosis in both hrTRAIL and mrTRAIL 
experiments in a dose dependent manner. Specifically, a concentration of 62.5 ng/mL 
hrTRAIL or mrTRAIL administered to seeded cells for a 3 day period demonstrates 
TRAIL’s ability to induce apoptosis (using serial dilutions) in WM793 (Figure 1A and 
1B), MDA-MB-231 (Figure 2A and 2B), and MCF-7 (Figure 3A and 3B) cell lines as 
compared to cells not given TRAIL. UMD227, Hs578T, and 4T1 cell lines did not show 
a change in cell density when an administered human or mouse TRAIL (results not 
shown). Cell densities were determined using the SRB protocol described in section 2.2.4 
of this manuscript. Cell density on day 3 was determined in the following way: a mean 
cell density was corrected for by subtracting the mean cell density of all day zero values 
obtained for each cell type (i.e. all WM793 day 0 values used in the mouse experiment) 
before the treatment means and standard deviations were calculated. The correction was 
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made this way to account for inter-day seeding variation that could occur as a result of 
plating the same cell line on different days.  
The results clearly show that recombinant TRAIL had an effect on human cell 
lines regardless of the species of origin. MDA-MB-231, MCF-7, and WM793 cell lines 
displayed reduced cell number after 3 days of treatment with the positive control 
commercially available recombinant TRAIL derived from either, human or mouse 
sequences. Susceptibility for MDA-MB-231, MCF-7, and WM793 cell lines were seen at 
62.5ng/mL commercial TRAIL after a 3 day period. Individual experiments are presented 
in Tables 9-14 and summarized results in Figures 1-3 (Tables 9-14; Figures 1-3) Not only 
were cell densities greatly reduced as measured by SRB assays, but floating debris was 
visible microscopically indicating cell death.  
 
Table 9- Corrected values obtained from Commercial human TRAIL on WM793 
 Day 0 0ng/mL 0.625 6.25 62.5 
Experiment 1 0.000 0.490 0.490 0.186 0.075 
Experiment 2 0.000 0.399 0.368 0.164 0.037 
Experiment 3 0.000 0.384 0.433 0.414 0.180 
Experiment 4 0.000 0.569 0.584 0.400 0.205 
 
 
 
Table 10- Corrected values obtained from of Commercial mouse TRAIL on WM793 
 Day 0 0ng/mL 0.625 6.25 62.5 
Experiment 1 0.000 0.611 0.464 0.077 0.025 
Experiment 2 0.000 0.683 0.408 0.003 0.000 
Experiment 3 0.000 0.495 0.406 0.105 0.024 
Experiment 4 0.000 0.318 0.341 0.200 0.004 
Experiment 5 0.000 0.462 0.443 0.193 0.048 
Experiment 6 0.000 0.511 0.489 0.188 0.068 
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Figure 1 – Commercially available human (Fig. 1A) and mouse (Fig. 1B) recombinant 
TRAIL and the effect of varying concentrations on WM793 melanoma cancer cells over 
a 3 day period as compared to cells not receiving the TRAIL protein. Plates were 
analyzed using SRB protocol and data from Tables 9 and 10 are graphed as mean ± s.d. 
(Human  n=4 and Mouse n=6)   
 
 
 
Table 11- Corrected values obtained from Commercial human TRAIL on MDA-MB 231 
 Day 0 0ng/mL 0.625 6.25 62.5 
Experiment 1 0.000 0.489 0.579 0.405 0.039 
Experiment 2 0.000 0.461 0.466 0.276 0.016 
Experiment 3 0.000 0.405 0.411 0.389 0.140 
Experiment 4 0.000 0.582 0.607 0.556 0.206 
 
 
 
 
Table 12- Corrected values obtained from Commercial mouse TRAIL on MDA-MB 231 
 Day 0 0ng/mL 0.625 6.25 62.5 
Experiment 1 0.000 0.355 0.398 0.292 0.075 
Experiment 2 0.000 0.598 0.568 0.340 0.046 
Experiment 3 0.000 0.574 0.542 0.415 0.078 
Experiment 4 0.000 0.521 0.521 0.483 0.214 
Experiment 5 0.000 0.434 0.421 0.417 0.248 
Experiment 6 0.000 0.595 0.615 0.579 0.289 
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Figure 2 – Commercially available human (Fig. 2A) and mouse (Fig. 2B) recombinant 
TRAIL and the effect of varying concentrations on MDA-MB 231 Human Breast Cancer 
cells over a 3 day period as compared to cells not receiving the TRAIL protein. Plates 
were analyzed using SRB protocol and data from Tables 11 and 12 are graphed as mean 
± s.d. (Human n=4 and Mouse n=6)   
 
 
Table 13- Corrected values obtained from Commercial human TRAIL on MCF-7 
 Day 0 0ng/mL .625 6.25 62.5 
Experiment 1 0.000 0.945 1.009 0.789 0.264 
Experiment 2 0.000 1.221 1.179 1.030 0.396 
Experiment 3 0.000 1.069 1.113 1.030 0.604 
Experiment 4 0.000 1.015 1.030 0.983 0.587 
 
 
 
 
Table 14- Corrected values obtained from Commercial mouse TRAIL on MCF-7 
 Day 0 0ng/mL .625 6.25 62.5 
Experiment 1 0.000 0.796 0.833 0.651 0.381 
Experiment 2 0.000 1.363 1.382 1.004 0.694 
Experiment 3 0.000 1.030 0.964 0.674 0.388 
Experiment 4 0.000 1.219 1.146 1.053 0.755 
Experiment 5 0.000 1.135 1.130 1.079 0.767 
Experiment 6 0.000 1.077 1.059 0.987 0.640 
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Figure 3 – Commercially available human (Fig. 3A) and mouse (Fig. 3B) recombinant 
TRAIL and the effect of varying concentrations on MCF-7 Human Breast Cancer cells 
over a 3 day period as compared to cells not receiving the TRAIL protein. Plates were 
analyzed using SRB protocol and data data from Tables 13 and 14 are graphed as mean ± 
s.d. (Human n=4 and Mouse n=6)   
 
 The sensitivity of several cancer lines to TRAIL encouraged the concept of 
engineering hrTRAIL in mesenchymal stem cells for use as a means to deliver anti-
cancer gene therapy to specific sites. Below I describe the in vitro biological activity of 
hrTRAIL which I engineered and expressed in CHO cells. 
 
3.3 - Biological activity of hrTRAIL 
 Engineered hrTRAIL was produced by transfected CHO cells. The quantity of 
TRAIL production was determined by measuring the secreted TRAIL in “conditioned” 
media using enzyme-linked immunosorbent assay (ELISA). Specifically, media was 
collected from CHO cells that were transfected with hrTRAIL as well as media from 
several control CHO lines which included transfected CHO cells, GFP transfected CHO 
cells, and cell free 50% fresh/ 50% aged media were below level of detection. The 
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TRAIL containing media collected from transfected CHO cells was processed as 
described in the Materials and Methods of this manuscript. The concentration of 
hrTRAIL in transfected CHO cells was 4.6 ng/mL while levels were below detection in 
all control CHO cell groups. 
 Thereafter the effect of hrTRAIL conditioned media on cancer cell line growth 
was measured using SRB assays. Cancer cell lines tested for effects of 100% and 50% 
hrTRAIL conditioned media included MDA-MB-231, MCF-7, and WM793 cells. Neither 
MDA-MB-231 nor MCF-7 cells responded to hrTRAIL conditioned medium but cell 
density after 96h of cell culture was reduced in WM793 cells grown in the presence of 
100% conditioned medium containing hrTRAIL.  
 
 
Table 15- SRB data on WM793 cells following treatment from media collected from 
transfected CHO cell producing GFP, hrTRAIL, or a media composed of a 50:50 ratio of 
the GFP and hrTRAIL conditioned media   
 GFP 
media 
50:50 100% hrTRAIL 
media 
Day 0 0.076 0.079 0.080 
Day 1 0.160 0.150 0.127 
Day 3 0.305 0.215 0.192 
Day 4 0.379 0.244 0.199 
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Figure 4 - The conditioned media from CHO cells transfected with GFP or hrTRAIL 
affected the final SRB results in a dose response relationship. Values were collected daily 
starting at day 0 (T=0), 24 hours after seeding and seeded with fresh 50:50 F12:DMEM 
media. (▲ = 100% hrTRAIL media ● = 100% GFP media, and ■ = 50% GFP/50% 
hrTRAIL media) Data points = mean ± s.d. (n=3). 
 
 
3.4 - Engineered IFNb conditioned media may decrease cell number of MDA-MB 
231 cells 
MDA-MB-231 cells showed a significant reduction in cell number when cultured 
in 100% media obtained from CHO cells producing hrIFNB as compared to media 
obtained from CHO cells producing GFP (Table 16). Statistical analysis using one tailed 
T-test was used with p-value <0.05 considered significant.  
Conditioned media containing IFNb was also used in cell lines that did not show a 
response to TRAIL in the initial commercial TRAIL studies (UMD 227 (murine 
mammary tumor cells), Hs578T (human breast tumor cells), and 4T1 (murine mammary 
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tumor cells)) as a possible sensitization step in a combinational approach to testing these 
cell lines. There was no change in the cell densities following the cells treated with 
conditioned media IFNb and commercial TRAIL as compared to treatments involving 
GFP media with TRAIL, TRAIL alone, fresh media alone, and GFP media alone 
following 4 days (data not shown). 
 
 
Table 16 –IFNb condition media experiment testing the effect of IFNb on MDA-MB 231 
Cells 
Experiment  GFP 50% 100% 
1 T=0 0.052 0.054 0.055 
 T=1 0.062 0.076 0.069 
 T=3 0.203 0.174 0.163 
 T=4 0.71 0.71 0.67 
     
2 T=0 0.050 0.051 0.054 
 T=1 0.094 0.074 0.069 
 T=3 0.273 0.167 0.142 
 T=4 0.81 0.74 0.63 
     
3 T=0 0.050 0.049 0.049 
 T=1 0.064 0.058 0.054 
 T=3 0.154 0.110 0.108 
 T=4 0.65 0.52 0.49 
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4. Discussion 
The cause of TRAIL susceptibility was not determined in this study for the cell 
lines of interest, but previous literature suggests that TRAIL receptor level surface 
expression of TRAIL-R1, TRAIL-R2, and the absence of decoy receptors (Sheridan et al. 
1997, Pan et al. 1997b, and Emery et al. 1998) and the presence of downstream apoptotic 
mediators as major determinants of TRAIL induced apoptotic response (Walczak et al. 
1997).  
This study demonstrated that a concentration of 62.5 ng/mL of human or mouse 
rTRAIL was able to significantly reduce the cell concentrations of MDA-MB-231, 
WM793, and MCF-7 cell lines over a 3 day period (Figures 1-3). Cell lines UMD227, 
Hs578T, and 4T1 that did not show a change in cell density to either mouse or human 
rTRAIL during the testing protocol of 62.5 ng/mL for 3 days also were subjected to a one 
time test of 1000 ng/mL environment for 3 days. In all cases, there appeared to be no 
apoptosis by observation with microscopy or reduction in cell number as assessed by the 
SRB assay (results not shown).  
The outcome regarding the MCF-7 cell line in this study differs from Rahman et 
al. (2009) in that they did not find a growth inhibition to MCF-7 cells with the 
administration of 1000ng/mL of TRAIL. Rahman et al. (2009) conducted western blot 
data for the presence of TRAIL-R1, -R2, -R3, -R4, and downstream mediators of TRAIL 
induced apoptosis. The western data for the TRAIL-R1 and -R2 receptors in the cell line 
Hs578T appear to be in lower quantity than obtained for MDA-MB-231 and MCF-7. 
Based on Rahman et al. (2009) data, my data suggests the functional presence of TRAIL-
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R1 and -R2 since the MCF-7 cells in my studies have the potential to be responsive to 
TRAIL (both human and mouse rTRAIL).  
WM793, a melanoma cell line, was shown to be the most susceptible to TRAIL 
out of the cell lines tested. It also demonstrated a susceptibility to TRAIL in a dose 
response manner with the TRAIL secreted from CHO cells that had been transfected with 
a mammalian expression vector containing the full length human TRAIL gene. This 
demonstrated our ability to synthesize TRAIL which is functionally similar to 
commercial products. ELISA studies confirmed that the 50:50 (F12:DMEM) media that 
was used, media taken from CHO cells, and media taken from CHO cells following a 
transfection with GFP did not contain hrTRAIL. These controls were used to make 
certain that TRAIL was not present in the media, produced by untransfected CHO cells, 
or produced in the media as a result of transfecting a plasmid into CHO cells. It is 
suggested from this data that if concentrations of hrTRAIL were to be increased, that it 
would have an effect on MDA-MB-231 cells, MCF-7, and any other cell line not studied 
in this experiment that is susceptible to TRAIL related apoptosis signaling.  
Conditioned media experiments using media from CHO cells that have been 
transfected with either hrIFNb or hrDecorin were also conducted. Although sequencing 
data indicates a successful amplification of both hrIFNb and hrDecorin, the results did 
not show a measurable result after four days of treatment using the SRB protocol to 
measure cell density after treatment. The absence of any significant response to the 
treatment of the cell lines used in this study with conditioned media of either hrIFNb or 
hrDecorin for four days indicate either an absence of functional protein produced, the cell 
types used are not susceptible to the antiproliferative or apoptotic effects of hrIFNb or 
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hrDecorin, or the experimental protocol described here was not sufficient to elicit the 
effects of hrIFNb or hrDecorin (i.e. low production levels of functional protein being 
produced in our CHO cell line). Future experiments with the engineered constructs 
should involve the use of protein specific ELISA tests to determine protein presence 
within the conditioned media and to correlate responses with highly purified 
commercially available proteins. Furthermore, my results suggest that the CHO-based 
production of these factors would be of benefit with the use of a regulatable and inducible 
protein production system in future in vivo studies. 
Many cancer treatments rely on the combination of surgery, radiation, and 
chemotherapy. Many times, a chemotherapy approach relies on a combination of drugs to 
be delivered at a particular time during a treatment cycle in the attempts to shrink or 
pretreat a cancer site prior to surgery, radiation, or the addition of another 
chemotherapeutic drug. Adjuvant, neoadjuvant, and combination chemotherapy 
regiments pose a significant potential for the future of the treatment of breast cancer and 
cancer as an entire disease entity. Cell based treatments represent an exciting future for 
the treatment of cancer as they have the possibility of delivering many gene products at 
the local level.  
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Appendix A – DNA Sequence of Factors 
 
hIFNb21 
SP6 
CCCTCTAGCAGTGGGAATTTCTTGTGTACCGAGCATCGGATCC
ATCTAGTAACGGCCGCCAGTGTGCTGGAATTCTGCAGATGGAT
CCTCAGTTTCGGAGGTAACCTGTAAGTCTGTTAATGAAGTAAA
AGTTCCTTAGGATTTCCACTCTGACTATGGTCCAGGCACAGTG
ACTGTACTCCTTGGCCTTCAGGTAATGCAGAATCCTCCCATAA
TATCTTTTCAGGTGCAGACTGCTCATGAGTTTTCCCCTGGTGAA
ATCTTCTTTCTCCAGTTTTTCTTCCAGGACTGTCTTCAGATGGT
TTATCTGATGATAGACATTAGCCAGGAGGTTCTCAACAATAGT
CTCATTCCAGCCAGTGCTAGATGAATCTTGTCTGAAAATAGCA
AAGATGTTCTGGAGCATCTCATAGATGGTCAATGCGGCGTCCT
CCTTCTGGAACTGCTGCAGCTGCTTAATCTCCTCAGGGATGTC
AAAGTTCATCCTGTCCTTGAGGCAATATCCAAGCCTCCCATTC
AATTGCCACAGGAGCTTCTGACACTGAAAATGGCTGCTTCTTT
GTAGGAATCCAAGCAAGTTGTAGCTCATGGAAAGAGCTGTAG
TGGAGAAGCACAACAGGAGAGCAATAAGGAGGAGACACTTGT
TGGTCATGGTGGATCCATCCATCACACTGGCGGCCGCTCGAGC
ATGCATCTAGAGGGGCCCATTTCGCCCTATTCGAAGTCGTATT
ACGAGTCACTGG 
hIFNb21 
M13For 
GGGTGGATCGGTATTCTCAATAGGGCGAATATGGGCCCTCTAG
ATGCATGCTCGAGCGGCCGCCAGTGTGATGGATGGATCCACC
ATGACCAACAAGTGTCTCCTCCAAATTGCTCTCCTGTTGTGCTT
CTCCACTACAGCTCTTTCCATGAGCTACAACTTGCTTGGATTCC
TACAAAGAAGCAGCAATTTTCAGTGTCAGAAGCTCCTGTGGCA
ATTGAATGGGAGGCTTGAATATTGCCTCAAGGACAGGATGAA
CTTTGACATCCCTGAGGAGATTAAGCAGCTGCAGCAGTTCCAG
AAGGAGGACGCCGCATTGACCATCTATGAGATGCTCCAGAAC
ATCTTTGCTATTTTCAGACAAGATTCATCTAGCACTGGCTGGA
ATGAGACTATTGTTGAGAACCTCCTGGCTAATGTCTATCATCA
GATAAACCATCTGAAGACAGTCCTGGAAGAAAAACTGGAGAA
AGAAGATTTCACCAGGGGAAAACTCATGAGCAGTCTGCACCT
GAAAAGATATTATGGGAGGATTCTGCATTACCTGAAGGCCAA
GGAGTACAGTCACTGTGCCTGGACCATAGTCAGAGTGGAAAT
CCTAAGGAACTTTAACTTCATTAACAGACTTACAGGTTACCTC
CGAAACTGAGGATCCATCTGCAGAATCCAGCACACTGGCGGG
CGTTACTAGTTGGATCCGAGCTCGGNACCCAAGCCTGAATGCA
TAGCCTGGAGTATTCTATAGGTG 
68 
hIFNb24 
M13Rev 
GTGGGGCGCAAGTCATTTAGGTGACACTATAGAATACTCAAG
CTATGCATCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACG
GCCGCCAGTGTGCTGGAATTCTGCAGATGGATCCTCAGTTTCG
GAGGTAACCTGTAAGTCTGTTAATGAAGTAAAAGTTCCTTAGG
ATTTCCACTCTGACTATGGTCCAGGCACAGTGACTGTACTCCT
TGGCCTTCAGGTAATGCAGAATCCTCCCATAATATCTTTTCAG
GTGCAGACTGCTCATGAGTTTTCCCCTGGTGAAATCTTCTTTCT
CCAGTTTTTCTTCCAGGACTGTCTTCAGATGGTTTATCTGATGA
TAGACATTAGCCAGGAGGTTCTCAACAATAGTCTCATTCCAGC
CAGTGCTAGATGAATCTTGTCTGAAAATAGCAAAGATGTTCTG
GAGCATCTCATAGATGGTCAATGCGGCGTCCTCCTTCTGGAAC
TGCTGCAGCTGCTTAATCTCCTCAGGGATGTCAAAGTTCATCC
TGTCCTTGAGGCAATATTCAAGCCTCCCATTCAATTGCCACAG
GAGCTTCTGACACTGAAAATTGCTGCTTCTTTGTAGGAATCCA
AGCAAGTTGTAGCTCATGGAAAGAGCTGTAGTGGAGAAGCAC
AACAGGAGAGCAATTTGGAGGAGACACTTGTTGGTCATGGGT
GGATCCATCCATCAC 
hIFNb24 
M13For 
TTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATG
GATGGATCCACCATGACCAACAAGTGTCTCCTCCAAATTGCTC
TCCTGTTGTGCTTCTCCACTACAGCTCTTTCCATGAGCTACAAC
TTGCTTGGATTCCTACAAAGAAGCAGCAATTTTCAGTGTCAGA
AGCTCCTGTGGCAATTGAATGGGAGGCTTGAATATTGCCTCAA
GGACAGGATGAACTTTGACATCCCTGAGGAGATTAAGCAGCT
GCAGCAGTTCCAGAAGGAGGACGCCGCATTGACCATCTATGA
GATGCTCCAGAACATCTTTGCTATTTTCAGACAAGATTCATCT
AGCACTGGCTGGAATGAGACTATTGTTGAGAACCTCCTGGCTA
ATGTCTATCATCAGATAAACCATCTGAAGACAGTCCTGGAAGA
AAAACTGGAGAAAGAAGATTTCACCAGGGGAAAACTCATGAG
CAGTCTGCACCTGAAAAGATATTATGGGAGGATTCTGCATTAC
CTGAAGGCCAAGGAGTACAGTCACTGTGCCTGGACCATAGTC
AGAGTGGAAATCCTAAGGAACTTTTACTTCATTAACAGACTTA
CAGGTTACCTCCGAAACTGAGGATCATCTGCAGAATCCAGCAC
ACTGGCGGCCGTTACTAGTGGATCNAGCTCGGTACCAGCCTGA
TGCATAGCCTGAGTATTCTATAGTGTCACCTAATAGCTGGGCG
TAATATTGNCATAGCTGTNTCGGG 
69 
hDecorin
1 SP6 
GTCATTGTTGTGGTGGCATGAAAACTACAGAATACCTATTAAT
TACCAGGCCGCCGGATGTGCTGGAATTCTGCAGATGGATCCAC
CATGAAGGCCACTATCATCCTCCTTCTGCTTGCACAAGTTTCCT
GGGCTGGACCGTTTCAACAGAGAGGCTTATTTGACTTTATGCT
AGAAGATGAGGCTTCTGGGATAGGCCCAGAAGTTCCTGATGA
CCGCGACTTCGAGCCCTCCCTAGGCCCAGTGTGCCCCTTCCGC
TGTCAATGCCATCTTCGAGTGGTCCAGTGTTCTGATTTGGGTCT
GGACAAAGTGCCAAAGGATCTTCCCCCTGACACAACTCTGCTA
GACCTGCAAAACAACAAAATAACCGAAATCAAAGATGGAGAC
TTTAAGAACCTGAAGAACCTTCACGCATTGATTCTTGTCAACA
ATAAAATTAGCAAAGTTAGTCCTGGAGCATTTACACCTTTGGT
GAAGTTGGAACGACTTTATCTGTCCAAGAATCAGCTGAAGGA
ATTGCCAGAAAAAATGCCCAAAACTCTTCAGGAGCTGCGTGC
CCATGAGAATGAGATCACCAAAGTGCGAAAAGTTACTTTCCAT
GGACTGAAACAGATGATTGTCATAGAACTGGGCACCCATTCG
CTGAAGAGCTCAGGAATTGAAATGGGGCCTTCCAGGGAATGA
GCAAGCTCTTCTACATTCGCATTGCTGATTCCATTATCACCAGC
ATGCCC 
hDecorin
1 
M13For 
GTGGATCTTTATTCTCAATAGGGGCGAATTGGGCCCTCTAGAT
GCATGCTCGAGCGGCCGCCAGTGTGATGGATGATCCTTACTTA
TAGTTTCCGAGTTGAATGGCAGAGCGCACGTAGACACATCTGA
AGGTGGATGGCTGTATCTCCCAGTACTGGACCGGGTTGCTGAA
AAGACTCACACCCGAATAAGAAGCCTTTTTGGTGTTGTGTCCA
GGTGGGCAGAAGTCACTTGATCCAACTACAGAGATATTGTTGT
TATGAAGGTAGACAACCTGGATGTACTTATGCTCTGCCAGCCC
ACCAGGTACTCTGGTAAGCTTGTTGTTGTCCAAGTGAAGCTCC
CTCAGATGAGGCGTGTTGGCCAGAGAGCCATTGTCAACAGCA
GAGATGCTGTTGAAACTCAATCCCAACTTAGCCAAATTATTCA
GTCCTTTCAGGCTAGCTGCATCAACTCTGCTGATTTTGTTGCCA
TCAAGATGTAATTCCGTAAGGGAAGGAGGAAGACCTTGAGGA
ATGCTGGTGATATTGGTATCAGCAATGCGGATGTAGGAGAGCT
TCTTCATTCCCTGGAAAGCCCCATTTTCAATTCCTGAGCTCTTC
AGCGGATTGGTGCCCAGTTCTATGACAATCATCTGGTTCAGTC
CATTGAAAGTAACTTTTCGCACCTTGGGTGATCTCATTCTCATT
GGGCACGCAGCTCCTGAAGAGTTTTTGGGCATTTTTTCTTGGC
AATCCCTCAGCTGATTCTTGGACCGATTANGTCGTCCCACCTC 
70 
hDecorin
2 
M13Rev 
GCCAATTCTATTTAGGTGACACTATAGAATACTCAAGCTATGC
ATCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCC
AGTGTGCTGGAATTCTGCAGATGGATCCACCATGAAGGCCACT
ATCATCCTCCTTCTGCTTGCACAAGTTTCCTGGGCTGGACCGTT
TCAACAGAGAGGCTTATTTGACTTTATGCTAGAAGATGAGGCT
TCTGGGATAGGCCCAGAAGTTCCTGATGACCGCGACTTCGAGC
CCTCCCTAGGCCCAGTGTGCCCCTTCCGCTGTCAATGCCATCTT
CGAGTGGTCCAGTGTTCTGATTTGGGTCTGGACAAAGTGCCAA
AGGATCTTCCCCCTGACACAACTCTGCTAGACCTGCAAAACAA
CAAAATAACCGAAATCAAAGATGGAGACTTTAAGAACCTGAA
GAACCTTCACGCATTGATTCTTGTCAACAATAAAATTAGCAAA
GTTAGTCCTGGAGCATTTACACCTTTGGTGAAGTTGGAACGAC
TTTATCTGTCCAAGAATCAGCTGAAGGAATTGCCAGAAAAAAT
GCCCAAAACTCTTCAGGAGCTGCGTGCCCATGAGAATGAGAT
CACCAAAGTGCGAAAAGTTACTTTCAATGGACTGAACCAGAT
GATTGTCATAGAACTGGGCACCANTCCGCTGAAGAGCTCAGG
AATTGAAATTGGGGCCTTCCAGGGGAATGAAGAAGCTCCTCCT
ACATTTCGCATTTGCCTGA 
hDecorin
2 
M13For 
ATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGAT
GGATGGATCCTTACTTATAGTTTCCGAGTTGAATGGCAGAGCG
CACGTAGACACATCTGAAGGTGGATGGCTGTATCTCCCAGTAC
TGGACCGGGTTGCTGAAAAGACTCACACCCGAATAAGAAGCC
TTTTTGGTGTTGTGTCCAGGTGGGCAGAAGTCACTTGATCCAA
CTACAGAGATATTGTTGTTATGAAGGTAGACAACCTGGATGTA
CTTATGCTCTGCCAGCCCACCAGGTACTCTGGTAAGCTTGTTG
TTGTCCAAGTGAAGCTCCCTCAGATGAGGCGTGTTGGCCAGAG
AGCCATTGTCAACAGCAGAGATGCTGTTGAAACTCAATCCCAA
CTTAGCCAAATTATTCAGTCCTTTCAGGCTAGCTGCATCAACT
CTGCTGATTTTGTTGCCATCAAGATGTAATTCCGTAAGGGAAG
GAGGAAGACCTTGAGGAATGCTGGTGATATTGGTATCAGCAA
TGCGGATGTAGGAGAGCTTCTTCATTCCCTGGAAAGCCCCATT
TTCAATTCCTGAGCTCTTCAGCGGATGGGTGCCCAGTTCTATG
ACAATCATCTGGTTCAGTCCATTGAAAGTAACTTTTCGCACCT
TGGGTGATCTCATTCTCATTGGGCACGCAGCCTCCTGAAGAGT
TTTTGGGCATTTTTTTCTTGGCCANTTCCNTTCAGCCTGATTTC
TTGG 
71 
hTRAIL 
3.2 A1-
A2 combi 
1 For 
TAATTCAGCCACTATAGGGCGAATTGGGCCCGACGTCGCATGC
TCCCGGCCGCCATGGCGGCCGCGGGAATTCGATTGGATCCTAG
CCAACTAAAAAGGCCCCGAAAAAACTGGCTTCATGGTCCATG
TCTATCAAGTGCTCATTTGTTACAGAAACAAAAATTCTGTCAT
TTTCCTTAAGCTCAAATATTCCCCCTTGATAGATGGAATAGAG
TCCATATTCTGCATCTTTAGACCAACAACTATTTCTAGCACTTT
TCATCAACAATATAGGGTCAGGATAACTTGTGTATTTGTAAAT
ATATTGGACCATTTGTTTGTCGTTCTTTGTGTTTTCTTTTATTTC
CTCCTGAAATCGAAAGTATGTTTGGGAATAGATGTAGTAAAAC
CCTTTTTCATGGATGACCAGTTCACCATTCCTCAAGTGCAAGTT
GCTCAGGAATGAATGCCCACTCCTTGATGATTCCCAGGAGTTT
ATTTTGCGGCCCAGAGCCTTTTCATTCTTGGAGTTTGGAGAAG
ACAATGTGTTGCTTCTTCCTCTGGTCCCAGTTATGTGAGCTGCT
ACTCTCTGAGGACCTCTTTCTCTCACTAGGGGAGAAATATTTT
GTTGCTTTTCTTGAACTGTAGAAATGGTTTCCTCAGAGGTTCTC
AAAATCATCTTTCTAACGAGCTGACGGAGTTGCNCTTGACTTG
CCAGCAGGGGCTGTCATACTCTCTTCGTCATTGGGGTCCCATT
T 
hTRAIL 
3.2 A1-
A2 combi 
1 rev 
TATTTAGGTGACACTATAGAATACTCAAGCTATGCATCCAACG
CGTGGGGAGCTCTCCCATATGGTCGACCTGCAGGCGGCCGCG
AATTCACTAGTGATTGGATCCACCATGGCTATGATGGAGGTCC
AGGGGGGACCCAGCCTGGGACAGACCTGCGTGCTGATCGTGA
TCTTCACAGTGCTCCTGCAGTCTCTCTGTGTGGCTGTAACTTAC
GTGTACTTTACCAACGAGCTGAAGCAGATGCAGGACAAGTAC
TCCAAAAGTGGCATTGCTTGTTTCTTAAAAGAAGATGACAGTT
ATTGGGACCCCAATGACGAAGAGAGTATGAACAGCCCCTGCT
GGCAAGTCAAGTGGCAACTCCGTCAGCTCGTTAGAAAGATGA
TTTTGAGAACCTCTGAGGAAACCATTTCTACAGTTCAAGAAAA
GCAACAAAATATTTCTCCCCTAGTGAGAGAAAGAGGTCCTCA
GAGAGTAGCAGCTCACATAACTGGGACCAGAGGAAGAAGCAA
CACATTGTCTTCTCCAAACTCCCAGAATGAAAAGGCTCTGGGC
CGCAAAATAAACTCCTGGGAATCATCAAGGAGTGGGCATTCA
TTCCTGAGCCACTTGCACTTGAGGAATGGTGAACTGGTCATCC
ATGAAAAAGGGTTTACTACATCTATTCCCAACATACTTCCGAT
NCAGGAGGAAATAAAGAAACCCCAAGAACGACAAACAAATG
GTCCATATATTTACAATTACCCAGGG 
72 
hTRAIL 
3.2 A1-
A2 combi 
4 For 
CTATAGGGCGAATTGGGCCCGACGTCGCATGCTCCCGGCCGCC
ATGGCGGCCGCGGGAATTCGATTGGATCCTAGCCAACTAAAA
AGGCCCCGAAAAAACTGGCTTCATGGTCCATGTCTATCAAGTG
CTCATTTGTTACAGAAACAAAAATTCTGTCATTTTCCTTAAGCT
CAAATATTCCCCCTTGATAGATGGAATAGAGTCCATATTCTGC
ATCTTTAGACCAACAACTATTTCTAGCACTTTTCATCAACAAT
ATAGGGTCAGGATAACTTGTGTATTTGTAAATATATTGGACCA
TTTGTTTGTCGTTCTTTGTGTTTTCTTTTATTTCCTCCTGAAATC
GAAAGTATGTTTGGGAATAGATGTAGTAAAACCCTTTTTCATG
GATGACCAGTTCACCATTCCTCAAGTGCAAGTTGCTCAGGAAT
GAATGCCCACTCCTTGATGATTCCCAGGAGTTTATATTGCGGC
CCAGAGCCTTTTCATTCTTGGAGTTTGGAGAAGACAATGTGTT
GCTTCTTCCTCTGGTCCCAGTTATGTGAGCTGCTACTCTCTGAG
GACCTCTTTCTCTCACTAGGGGAGAAATATTTTGTTGCTTTTCT
AGAACTGTAGAAATGGTTTCCTCAGAGGTTCTCAAAATCATCT
ATCTAACGAGCTGACGGAGTTGCCACTAGACTTGCCAGCAGG
GGCTGTTCATACTCTCATTCGTCATNGGGGGTCCCAATAACTG
TCATCTACATATTAAGAAACAAGCCAATGCCACATTTG 
hTRAIL 
3.2 A1-
A2 combi 
4 rev 
TATTGTAGGTTGACACTATAGGCATACTCAAGCTATGCATGCA
ACGCGTGGGGAGCCTCTCCCATATGGGTCGACCTGCAGGCGG
CCGCGAATGTCACTAGTGATTGGATCCACCATGGCTATGATGG
AGGTCCAGGGGGGACCCAGCCTGGGACAGACCTGCGTGCTGA
TCGTGATCTTCACAGTGCTCCTGCAGTCTCTCTGTGTGGCTGTA
ACTTACGTGTACTTTACCAACGAGCTGAAGCAGATGCAGGAC
AAGTACTCCAAAAGTGGCATTGCTTGTTTCTTAAAAGAAGATG
ACAGTTATTGGGACCCCAATGACGAAGAGAGTATGAACAGCC
CCTGCTGGCAAGTCAAGTGGCAACTCCGTCAGCTCGTTAGAAA
GATGATTTTGAGAACCTCTGAGGAAACCATTTCTACAGTTCAA
GAAAAGCAACAAAATATTTCTCCCCTAGTGAGAGAAAGAGGT
CCTCAGAGAGTAGCAGCTCACATAACTGGGACCAGAGGAAGA
AGCAACACATAGTCTTCTCCAAACTCCAAGAATGAAAAGGCT
CTGGGCCGCAAAATAAACTCCTGGGAATCATCAAGGAGTGGG
CATTCATACCTGAGCAACTTGCACTTGAGGAATGGTGAACTGG
TCATCCATGAAAAAAGGGTTTTACTACATCTATTCCCCAAACA
TACTTTTCGAATTTCAGGGAAGGAAATTAAAAAGAAAAACCC
CCAANGAACCC 
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